|
ý
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
71-0869350
(IRS Employer
Identification Number)
|
1 Cedar Brook Drive, Cranbury, NJ
(Address of Principal Executive Offices)
|
|
08512
(Zip Code)
|
(609) 662-2000
(Registrant's Telephone Number, Including Area Code)
|
Title of each class
|
Name of each exchange on which registered
|
Common Stock, par value $0.01 per share
|
The NASDAQ Stock Market LLC
|
Large accelerated filer
ý
|
|
Accelerated filer
o
|
Non-accelerated filer
o
|
|
Smaller reporting company
o
|
|
|
Emerging growth company
o
|
|
•
|
the progress and results of our preclinical and clinical trials of our drug candidates;
|
•
|
the cost of manufacturing drug supply for our clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy (“ERT”) and gene therapies;
|
•
|
the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates including those testing the use of pharmacological chaperones co-formulated and co-administered with ERT and for the treatment of lysosomal storage disorders and gene therapies for the treatment of rare genetic metabolic diseases;
|
•
|
the future results of on-going preclinical research and subsequent clinical trials for cyclin-dependent kinase-like 5 (“CDKL5”) deficiency, including our ability to obtain regulatory approvals and commercialize CDKL5 therapies and obtain market acceptance for such therapies;
|
•
|
the costs, timing and outcome of regulatory review of our product candidates;
|
•
|
the number and development requirements of other product candidates that we pursue;
|
•
|
the costs of commercialization activities, including product marketing, sales and distribution;
|
•
|
the emergence of competing technologies and other adverse market developments;
|
•
|
our ability to successfully commercialize Galafold
®
(“migalastat HCl”);
|
•
|
our ability to manufacture or supply sufficient clinical or commercial products;
|
•
|
our ability to obtain reimbursement for Galafold
®
;
|
•
|
our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold
®
;
|
•
|
our ability to obtain market acceptance of Galafold
®
;
|
•
|
the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;
|
•
|
the extent to which we acquire or invest in businesses, products and technologies;
|
•
|
our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;
|
•
|
our ability to establish collaborations and obtain milestone, royalty or other payments from any such collaborators;
|
•
|
our ability to adjust to changes in European and United Kingdom markets as the United Kingdom leaves the European Union; and
|
•
|
fluctuations in foreign currency exchange rates; and changes in accounting standards.
|
•
|
Commercial and regulatory success in Fabry disease
. During the year ended
December 31, 2018
, Galafold
®
revenue totaled approximately
$91.2 million
. Revenue has been generated primarily in the EU since May of 2016. In 2018, we received approvals for Galafold
®
in the U.S. and Japan.
|
•
|
Pompe clinical program milestones
. We reported a series of positive data from a Phase 1/2 clinical study to evaluate Pompe disease patients treated with our novel treatment paradigm AT-GAA for up to 18 months. We also initiated a global pivotal study of AT-GAA (ATB200-03, also known as PROPEL) which is expected to enroll approximately 100 participants with late-onset Pompe disease at up to 90 global sites.
|
•
|
Pipeline Growth:
With 14 new gene therapy programs for LSDs, we have established a leading portfolio of medicines for people living with rare metabolic disorders. Through our license with NCH, we acquired worldwide development and commercial rights for ten gene therapy programs in rare, neurologic LSDs with lead programs in CLN6, CLN3, and CLN8 Batten disease. An additional four programs were added to the pipeline through the collaboration
with Penn to pursue research and development of novel gene therapies for Pompe disease, Fabry disease, CDKL5 deficiency disorder (“CDD”) and one additional undisclosed rare metabolic disorder.
|
•
|
Manufacturing
. We successfully scaled up manufacturing of our Pompe biologic to commercial scale (1,000L) for our pivotal PROPEL study and commercial supply. Our supply agreement with WuXi Biologics and current capacity are expected to produce sufficient quantities to serve the entire Pompe population as quickly as possible after receipt of applicable regulatory approvals. Through our collaborations with NCH and Penn, we also gain access to their preclinical manufacturing capabilities, clinical supply and CMO relationships for those gene therapy programs.
|
•
|
Financial strength.
Total cash, cash equivalents and marketable securities of
$504.2 million
at
December 31, 2018
compared to
$358.6 million
at
December 31, 2017
. The current cash position, including expected Galafold
®
revenues, is sufficient to fund ongoing Fabry, Pompe and gene therapy program operations into at least mid-2021. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.
|
•
|
We have an exclusive license to a number of issued U.S. patents that cover the use of Galafold
®
to treat Fabry disease, as well as corresponding European, Japanese, and Canadian patents. These exclusively licensed U.S. patents relating to Galafold
®
expired in 2018, while the European, Japanese, and Canadian patents will expire in 2019. The patents include claims covering methods of increasing the activity of and preventing the degradation of alpha-Gal A, and methods for the treatment of Fabry disease using Galafold
®
. In addition, we own two issued U.S. patents directed to dosing regimens with Galafold
®
that expire in 2027 (not including any extensions), as well as a pending application which, if granted, may result in a patent that also expires in 2027 (not including any extensions). Foreign counterpart patents are issued in Australia, Europe, Hong Kong, Mexico, and Japan, and foreign applications are pending in Australia, Canada, Europe, Hong Kong, Japan, and Mexico. Further, we own an issued U.S. patent directed to synthetic steps related to the commercial process for preparing Galafold
®
, which expires in 2026, as well as issued patents in China, Europe, Hong Kong, India, Israel, and Japan. We jointly own issued U.S., European, Hong Kong, and Mexican patents covering a method of determining whether male Fabry disease patients are likely to respond to treatment with Galafold
®
which expires in 2027. We have two issued U.S. patents covering a method of treating a patient diagnosed with Fabry disease with Galafold
®
wherein the Fabry patient has one of several alpha-Gal A variants. These patents will expire in 2029. We also have a pending U.S. application covering a method of determining which alpha-Gal A variants are likely to be amenable to therapy with Galafold
®
which, if granted, will expire in 2029. Foreign counterpart patents have also been issued in Europe, Japan, Canada, Mexico, and Australia; all of which will also expire in 2029. We also have filed a patent application covering a method of treating renal symptoms in a Fabry patient in relevant jurisdictions. As of February 2019, we have allowance of the U.S. counterpart and when granted, the patent would expired in 2038.
|
•
|
We have an exclusive license to pending patent applications covering the co-administration of Galafold
®
with ERT (recombinant alpha-Gal A). Patents covering specific combinations have issued in the U.S., Europe, Canada, China, India, Israel, Hong Kong, Japan, and Mexico. These issued patents will expire in 2024. We also own a U.S. patent application covering specific doses and dosing regimens of Galafold
®
to treat Fabry disease in combination with ERT (recombinant alpha-Gal A) in the U.S. and foreign counterpart applications in Australia, Canada, Europe, Hong Kong, Japan, and issued patents in Australia, Canada, and China. Any patents issuing from these applications will expire in 2032.
|
•
|
We have patents covering a co-formulation of recombinant acid alpha-glucosidase and Galafold
®
in the U.S. and Australia, as well as pending patent applications in the U.S., Australia, Canada, China, Europe, and Hong Kong. If patents issue from these applications, expiration will be in 2033 or 2034.
|
•
|
As part of the Callidus acquisition, we acquired a portfolio of patent applications including an application series covering reagents and methods for coupling targeting peptides to recombinant lysosomal enzymes, including recombinant acid alpha-glucosidase. Patents in this series are issued in the U.S., Canada, China and Europe, and applications are pending in the U.S., Europe, Japan, Brazil, Canada, China, and South Korea. If patents issue from these applications, expiration will be in 2032 to 2034 depending on the specific application.
|
•
|
Another patent application portfolio related to a modified lysosomal enzyme (acid alpha-glucosidase) that binds more effectively to the receptor and more potent than conventional recombinant enzymes. These applications pending in the U.S., Australia, Brazil, Canada, China, Eurasia, Europe, Israel, India, Japan, South Korea, Mexico, Singapore, Taiwan, South Africa, and other countries. If patents issue from this series, they will expire in 2035 to 2038.
|
•
|
As part of the acquisition of MiaMed, we acquired an exclusive worldwide license to certain patent rights held by the Università di Bologna. These patent rights include two issued U.S. patent and a pending U.S. patent application directed to novel CDD fusion proteins, as well as pending counterpart patent applications in several foreign countries. The issued U.S. patent and the patent applications, if issued, will expire in 2035.
|
•
|
From NCH through the acquisition of Celenex, we have an exclusive license to pending patent applications covering ten AAV program in neurodegenerative disorders, including CLN6, CLN3, and CLN8 Batten diseases. These patent rights include one issued European patent and several pending U.S. patent applications pertaining to various aspects of the gene therapy programs, as well as pending counterpart patent applications in several foreign countries. The issued European patent and the patent applications, if issued, will expire in 2033 or 2040.
|
•
|
The longer of 17 years from the issue date or 20 years from the earliest effective filing date, if the patent application was filed prior to June 8, 1995; and
|
•
|
20 years from the earliest effective filing date, if the patent application was filed on or after June 8, 1995.
|
Competitor
|
Indication
|
|
Product
|
|
Class of Product
|
|
Status
|
|
2018 Sales
|
||
|
|
|
|
|
|
|
|
|
(in millions)
|
||
Sanofi Aventis
|
Fabry Disease
|
|
Fabrazyme
®
|
|
ERT
|
|
Marketed
|
|
$
|
742.5
|
|
Pompe Disease
|
|
Myozyme
®
/ Lumizyme
®
|
|
ERT
|
|
Marketed
|
|
$
|
827.5
|
|
|
Fabry Disease
|
|
GZ402671
|
|
Oral GCS Inhibitor
|
|
Phase 2
|
|
N/A
|
|
||
Pompe Disease
|
|
GZ402666 ("neo GAA")
|
|
ERT
|
|
Phase 3
|
|
N/A
|
|
||
Takeda
|
Fabry Disease
|
|
Replagal
®
|
|
ERT
|
|
Marketed
|
|
$
|
498.1
|
|
Protalix Biotherapeutics
|
Fabry Disease
|
|
PRX-102
|
|
ERT
|
|
Phase 2/3
|
|
N/A
|
|
|
Audentes
|
Pompe Disease
|
|
AT845
|
|
Gene Therapy
|
|
Preclinical
|
|
N/A
|
|
|
Sangamo
|
Fabry Disease
|
|
ST-920
|
|
Gene Therapy
|
|
Preclinical
|
|
N/A
|
|
|
Avrobio
|
Fabry Disease
|
|
AVR-RD-01
|
|
Gene Therapy
|
|
Phase 1/2
|
|
N/A
|
|
|
Pompe Disease
|
|
AVR-RD-03
|
|
Gene Therapy
|
|
Preclinical
|
|
N/A
|
|
||
Spark
|
Pompe Disease
|
|
SPK-3006
|
|
Gene Therapy
|
|
Preclinical
|
|
N/A
|
|
|
Abeona
|
CLN3 Batten
|
|
ABO-201
|
|
Gene Therapy
|
|
Preclinical
|
|
N/A
|
|
•
|
obtaining a sufficiently broad label in each territory that would not unduly restrict patient access;
|
•
|
obtaining additional foreign approvals for Galafold
®
;
|
•
|
continuing to build and maintain an infrastructure capable of supporting product sales, marketing, and distribution of Galafold
®
in the EU, U.S., Japan and other territories where we pursue commercialization directly;
|
•
|
maintaining commercial manufacturing arrangements with third party manufacturers;
|
•
|
maintaining commercial distribution agreements with third party distributors;
|
•
|
launching commercial sales of Galafold
®
, where approved, whether alone or in collaboration with others;
|
•
|
acceptance of Galafold
®
, where approved, by patients, the medical community and third party payors;
|
•
|
effectively competing with other therapies, including potential generics and potential gene therapies;
|
•
|
a continued acceptable safety profile of Galafold
®
;
|
•
|
obtaining and maintaining patent and trade secret protection and regulatory exclusivity;
|
•
|
protecting and enforcing our rights in our intellectual property portfolio; and
|
•
|
obtaining a commercially viable price for our products.
|
•
|
our failure to demonstrate to the satisfaction of the applicable regulatory authorities that any of our product candidates are safe and effective for a particular indication;
|
•
|
the results of clinical trials may not meet the level of statistical significance or other efficacy or safety parameters required by the applicable regulatory authorities for approval;
|
•
|
the applicable regulatory authority may disagree with the number, design, size, conduct, or implementation of our clinical trials or conclude that the data fail to meet statistical or clinical significance;
|
•
|
the applicable regulatory authority may not find the data from preclinical studies and clinical trials sufficient to demonstrate that the product candidate's clinical and other benefits outweigh its safety risks;
|
•
|
the applicable regulatory authority may disagree with our interpretation of data from preclinical studies or clinical trials, and may reject conclusions from preclinical studies or clinical trials, or determine that primary or secondary endpoints from clinical trials were not met, or reject safety conclusions from such studies or trials;
|
•
|
the applicable regulatory authority may not accept data generated at one or more of our clinical trial sites;
|
•
|
the applicable regulatory authority may determine that we did not properly oversee our clinical trials or follow the regulatory authority's advice or recommendations in designing and conducting our clinical trials;
|
•
|
an advisory committee, if convened by the applicable regulatory authority, may recommend against approval of our application or may recommend that the applicable regulatory authority require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve the product candidate; and
|
•
|
the applicable regulatory authority may identify deficiencies in the chemistry, manufacturing, and control sections of our application, our manufacturing processes, facilities, or analytical methods or those of our third party contract manufacturers, and this may lead to significant delays in the approval of our product candidates or to the rejection of our applications altogether.
|
•
|
regulatory authorities may require the addition of restrictive labeling statements;
|
•
|
regulatory authorities may withdraw their approval of the product; and
|
•
|
we may be required to change the way the product is administered or additional clinical trials are conducted.
|
•
|
our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
|
•
|
the inability of sales personnel to obtain access to adequate numbers of physicians to prescribe any future products;
|
•
|
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;
|
•
|
unforeseen costs and expenses associated with creating an independent sales and marketing organization; and
|
•
|
efforts by our competitors to commercialize products at or about the time when our product candidates would be coming to market.
|
•
|
we may not be able to control the amount and timing of resources that our distributors may devote to the commercialization of our product or product candidates;
|
•
|
our distributors may experience financial difficulties;
|
•
|
our distributors may experience compliance related issues and associated government investigations;
|
•
|
business combinations or significant changes in a distributor's business strategy may also adversely affect a distributor's willingness or ability to complete its obligations under any arrangement; and
|
•
|
these arrangements are often terminated or allowed to expire, which could interrupt the marketing and sales of a product and decrease our revenue.
|
•
|
the efficacy and potential advantages compared to alternative treatments, including generics and gene therapies;
|
•
|
the prevalence and severity of any side effects;
|
•
|
the ability to offer our product and product candidates for sale at competitive prices;
|
•
|
convenience and ease of administration compared to alternative treatments;
|
•
|
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
|
•
|
the strength of marketing and distribution support and timing of market introduction of competitive products;
|
•
|
publicity concerning our products or competing products and treatments; and
|
•
|
sufficient third party coverage or reimbursement.
|
•
|
different regulatory requirements for maintaining approval of drugs in foreign countries;
|
•
|
reduced protection for contractual and intellectual property rights in some countries;
|
•
|
unexpected changes in tariffs, trade barriers and regulatory requirements;
|
•
|
economic weakness, including inflation, or political instability in particular foreign economies and markets;
|
•
|
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
|
•
|
foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;
|
•
|
workforce uncertainty in countries where labor unrest is more common than in the U.S.;
|
•
|
noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anti-corruption laws in other jurisdictions;
|
•
|
tighter restrictions on privacy and the collection and use of patient data; and
|
•
|
business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.
|
•
|
restrictions on such products, manufacturers or manufacturing processes;
|
•
|
changes to or restrictions on the labeling or marketing of a product;
|
•
|
restrictions on product distribution or use;
|
•
|
requirements to implement a REMS;
|
•
|
requirements to conduct post-marketing studies or clinical trials;
|
•
|
warning or untitled letters;
|
•
|
withdrawal of the products from the market;
|
•
|
refusal to approve pending applications or supplements to approved applications that we submit;
|
•
|
recall of products;
|
•
|
fines, restitution or disgorgement of profits or revenues;
|
•
|
suspension or withdrawal of marketing approvals;
|
•
|
refusal to permit the import or export of our products;
|
•
|
product seizure;
|
•
|
injunctions; or
|
•
|
the imposition of civil or criminal penalties.
|
•
|
the U.S. federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Several other countries, including the United Kingdom, have enacted similar anti-kickback, fraud and abuse, and healthcare laws and regulations;
|
•
|
the U.S. federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. There is also a separate false claims provision imposing criminal penalties. Applicable regulations of both the EMA and EU member states also impose liability for failing to comply with fraud and abuse laws or improperly using information obtained in in the course of clinical trials with the EMA or other regulatory authorities;
|
•
|
The U.S. federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute to defraud any healthcare benefit program or specific intent to violate it in order to have committed a violation. This statute also may impose monetary penalties on any offers or transfers of remuneration to Medicare or Medicaid beneficiaries (patients) which is likely to influence the beneficiary's selection of particular supplier of government payable items. Similarly, the collection and use of personal health data in the EU is governed by the EU General Data Protection Regulation (the "GDPR"), with many requirements mandated by the GDPR for the consent of the individuals to whom the personal data relates, the information provided to the individuals, transfer of personal data within and outside of the EU and the security and confidentiality of the personal data. Enforcement of the GDPR began on May 25, 2018, and failure to comply with the requirements of the GDPR may result in substantial fines and other administrative penalties. The GDPR increases our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may be onerous and adversely affect our business, financial condition, results of operations and prospects;
|
•
|
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
|
•
|
U.S. federal laws requiring drug manufacturers to report annually information related to certain payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership or investment interests held by physicians and their immediate family members, including under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign laws regulating marketing activities and requiring manufacturers to report marketing expenditures, payments and other transfers of value to physicians and other healthcare providers. Similarly, payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician's employer, his or her competent professional organization and/or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU member states. In addition, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment;
|
•
|
U.S. federal government price reporting laws, which require us to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on our marketed drugs. Participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, potential liability for the failure to report such prices in an accurate and timely manner, and potentially limit our ability to offer certain marketplace discounts;
|
•
|
U.S. Foreign Corrupt Practices Act, which prohibit us and third parties working on our behalf from making payments to foreign government officials to assist in obtaining or retaining business. Specifically, the anti-bribery provisions of the FCPA prohibit the willful use of the mails or any means of instrumentality of interstate commerce corruptly in furtherance of any offer, payment, promise to pay, or authorization of the payment of money or anything of value to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to a foreign official to influence the foreign official in his or her official capacity, induce the foreign official to do or omit to do an act in violation of his or her lawful duty, or to secure any improper advantage in order to assist in obtaining or retaining business for or with, or directing business to, any person; and
|
•
|
state and foreign equivalents of each of the above laws, including foreign anti-bribery and corruption laws and state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
|
•
|
reduced resources of our management to pursue our business strategy;
|
•
|
decreased demand for any product candidates or products that we may develop;
|
•
|
injury to our reputation and significant negative media attention;
|
•
|
regulatory investigations, prosecutions or enforcement actions that could require costly recalls or product modifications;
|
•
|
withdrawal of clinical trial participants;
|
•
|
significant costs to defend the related litigation;
|
•
|
increased insurance costs, or an inability to maintain appropriate insurance coverage;
|
•
|
substantial monetary awards to trial participants or patients, including awards that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available, and would damage our ability to obtain liability insurance at reasonable costs, or at all, in the future;
|
•
|
loss of revenue; and
|
•
|
the inability to commercialize any products that we may develop.
|
•
|
choose not to seek regulatory approval in the U.S., EU or other key jurisdictions;
|
•
|
be delayed in obtaining marketing approval for our product candidates;
|
•
|
not obtain marketing approval at all;
|
•
|
obtain approval for indications or patient populations that are not as broad as intended or desired;
|
•
|
obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;
|
•
|
be subject to additional post-marketing testing requirements, safety strategies or restrictions, such as a requirement of a risk evaluation and mitigation strategy, or REMS; or
|
•
|
have the product removed from the market after obtaining regulatory approval.
|
•
|
clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;
|
•
|
the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or patients may drop out of these clinical trials at a higher rate than we anticipate;
|
•
|
we may be unable to enroll a sufficient number of patients in our trials to ensure adequate statistical power to detect any statistically significant treatment effects;
|
•
|
our third party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;
|
•
|
regulators, institutional review boards, or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
|
•
|
we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;
|
•
|
we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;
|
•
|
regulators, institutional review boards, or independent ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;
|
•
|
the cost of clinical trials of our product candidates may be greater than we anticipate;
|
•
|
the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; or
|
•
|
our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, institutional review boards or independent ethics committees to suspend or terminate the trials.
|
•
|
severity of the disease under investigation;
|
•
|
eligibility criteria for the clinical trial in question;
|
•
|
perceived risks and benefits of the product candidate under study;
|
•
|
efforts to facilitate timely enrollment in clinical trials;
|
•
|
patient referral practices of physicians;
|
•
|
the ability to monitor patients adequately during and after treatment; and
|
•
|
proximity and availability of clinical trial sites for prospective patients.
|
•
|
continue our development and commercialization of, and seek regulatory approvals for, product candidates in the U.S., the EU, Japan and other foreign countries, as applicable;
|
•
|
conduct additional clinical trials to support the full approval of Galafold
®
in the U.S. and post-approval commitments or trials;
|
•
|
continue communicating with the EMA, as necessary, regarding post-marketing requirements and clinical trials for Galafold
®
;
|
•
|
continue to or initiate the regulatory submission process for marketing approval of Galafold
®
outside of the U.S. and EU, as applicable;
|
•
|
build and maintain our commercial infrastructure so that it is capable of supporting product sales, marketing and distribution of Galafold
®
and our other product candidates in the EU, Japan and the U.S. or other territories in which we may receive regulatory approval;
|
•
|
continue wind-down of our Phase 3 clinical trial of SD-101 for the treatment of EB;
|
•
|
continue our preclinical studies and clinical trials on the use of AT-GAA for Pompe disease and our gene therapies for Fabry, Pompe, Batten’s and other LSDs; and
|
•
|
continue our preclinical studies of and potentially conduct clinical studies of ERT and gene therapy for CDD.
|
•
|
successfully complete development activities and obtain additional regulatory and pricing and reimbursement approvals for, and successfully commercialize, Galafold
®
;
|
•
|
develop and maintain a commercial organization capable of sales, marketing, and distribution for Galafold
®
and any product candidates we intend to market, in the countries where we have chosen to commercialize the product candidates ourselves including the U.S. and Japan;
|
•
|
manufacture commercial quantities of our products at acceptable cost levels;
|
•
|
obtain a commercially viable price for our products;
|
•
|
obtain coverage and adequate reimbursement from third-parties, including government payors;
|
•
|
successfully satisfy post-marketing requirements that the FDA, EMA, or other foreign regulatory authorities may impose for migalastat HCl
or any of our other product candidates that may receive regulatory approval, including pediatric trials and patient registries;
|
•
|
successfully complete development activities, including the necessary preclinical studies and clinical trials, with respect to product candidates, including AT-GAA and our gene therapies;
|
•
|
complete and submit regulatory submissions to the FDA and obtain regulatory approval for our product candidates including AT-GAA and our gene therapies; and
|
•
|
complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities.
|
•
|
significantly delay, scale back, or discontinue the development or the commercialization of our product or product candidates or one or more of our other research and development initiatives;
|
•
|
seek collaborators for Galafold
®
or one or more of our current or future product candidates at an earlier stage than otherwise would be desirable, or on terms that are less favorable than might otherwise be available;
|
•
|
relinquish or license on unfavorable terms our rights to our technologies, product or product candidates that we otherwise would seek to develop or commercialize ourselves; or
|
•
|
significantly curtail operations.
|
•
|
the costs of commercialization activities, including maintaining sales, marketing, and distribution capabilities for Galafold
®
and any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own;
|
•
|
the scope, progress, results, and costs of preclinical development, laboratory testing, and clinical trials for our product candidates and any other product candidates that we may in-license or acquire;
|
•
|
the cost of manufacturing drug supply for our preclinical studies and clinical trials, including the significant cost of manufacturing AT-GAA and our gene therapies;
|
•
|
the cost of transferring manufacturing technologies for our gene therapies to CMOs;
|
•
|
the outcome, timing, and cost of the regulatory approval process by the FDA, EMA, PMDA and other foreign regulatory authorities, including the potential for regulatory authorities to require that we perform more studies than those that we currently anticipate for our product and product candidates;
|
•
|
the cost of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights;
|
•
|
the cost and timing of completion of existing or expanded commercial-scale outsourced manufacturing activities;
|
•
|
the cost of defending any claims asserted against us;
|
•
|
the emergence of competing technologies and other adverse market developments;
|
•
|
the extent to which we acquire or invest in additional businesses, products, and technologies.
|
•
|
we or our licensors were the first to make the inventions covered by each of our pending patent applications;
|
•
|
we or our licensors were the first to file patent applications for these inventions;
|
•
|
others will not independently develop similar or alternative technologies or duplicate any of our technologies;
|
•
|
any patents issued to us or our licensors will provide a basis for commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;
|
•
|
licenses from other third parties will not be required to commercialize patented products;
|
•
|
we will develop additional proprietary technologies that are patentable;
|
•
|
we will file patent applications for new proprietary technologies promptly or at all;
|
•
|
our patents will not expire prior to or shortly after commencing commercialization of a product;
|
•
|
the patents of others will not have a negative effect on our ability to do business; or
|
•
|
patent authorities will not identify deficiencies in our patent applications and refuse to grant our patents.
|
•
|
We do not hold composition of matter patents covering Galafold
®
and we have method of manufacturing patent applications allowed for ATB200 as well as method of treatment patents allowed for migalastat HCl. There can be no assurance that the allowed applications will be issued or that the scope of such patents, if they issue, will be sufficient to protect our product. Composition of matter patents can provide protection for pharmaceutical products to the extent that the specifically covered compositions are important. For our product candidates for which we do not hold composition of matter patents, competitors who obtain the requisite regulatory approval can offer products with the same composition as our products so long as the competitors do not infringe any method of use patents that we may hold.
|
•
|
For some of our product candidates the principal patent protection that covers or those we expect will cover our product candidate is a method of use patent. This type of patent only protects the product when used or sold for the specified method. However, this type of patent does not limit a competitor from making and marketing a product that is identical to our product that is labeled for an indication that is outside of the patented method, or for which there is a substantial use in commerce outside the patented method.
|
•
|
reliance on the third party for regulatory compliance and quality assurance;
|
•
|
limitations on supply availability resulting from capacity and scheduling constraints of the third parties;
|
•
|
inability to demonstrate comparability to GMP commercial scale product for biologic products;
|
•
|
inability to manufacture batches that meet specifications and quality standards;
|
•
|
impact on our reputation in the marketplace if manufacturers of our products, once commercialized, fail to meet the demands of our customers;
|
•
|
the possible breach of the manufacturing agreement by the third party;
|
•
|
the possible misappropriation of our proprietary information, including our trade secrets and know-how; and
|
•
|
the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
|
•
|
collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
|
•
|
collaborators may not pursue development and commercialization of our product or product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;
|
•
|
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
|
•
|
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
|
•
|
a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;
|
•
|
collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;
|
•
|
collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;
|
•
|
disputes may arise between the collaborator and us as to the ownership of intellectual property arising during the collaboration;
|
•
|
we may grant exclusive rights to our collaborators, which would prevent us from collaborating with others;
|
•
|
disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and
|
•
|
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.
|
•
|
managing the development and commercialization of any product candidates approved for marketing;
|
•
|
overseeing our ongoing preclinical studies and clinical trials effectively;
|
•
|
identifying, recruiting, maintaining, motivating and integrating additional employees, including any sales and marketing personnel engaged in connection with the commercialization of any approved product;
|
•
|
managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties;
|
•
|
improving our managerial, development, operational and financial systems and procedures;
|
•
|
developing our compliance infrastructure and processes to ensure compliance with regulations applicable to public companies;
|
•
|
developing biologics and gene therapy manufacturing expertise; and
|
•
|
expanding our facilities.
|
•
|
FDA or similar regulations of foreign regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities;
|
•
|
manufacturing standards;
|
•
|
federal and state healthcare fraud and abuse laws and regulations, anti-bribery and corruption laws, and similar laws and regulations established and enforced by foreign regulatory authorities; or
|
•
|
laws that require the reporting of financial information or data accurately.
|
•
|
establish a classified board of directors, and, as a result, not all directors are elected at one time;
|
•
|
allow the authorized number of our directors to be changed only by resolution of our board of directors;
|
•
|
limit the manner in which stockholders can remove directors from our board of directors;
|
•
|
establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;
|
•
|
require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;
|
•
|
limit who may call stockholder meetings;
|
•
|
authorize our board of directors to issue preferred stock, without stockholder approval, which could be used to institute a "poison pill" that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and
|
•
|
require the approval of the holders of at least 67% of the outstanding voting stock to amend or repeal certain provisions of our charter or bylaws.
|
•
|
the success of competitive products or technologies;
|
•
|
regulatory actions with respect to our product or product candidates or our competitors' products or product candidates;
|
•
|
actual or anticipated changes in our growth rate relative to our competitors;
|
•
|
the outcome of any patent infringement or other litigation that may be brought against us;
|
•
|
announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;
|
•
|
results of clinical trials of our product candidates or those of our competitors;
|
•
|
regulatory or legal developments in the EU, U.S. and other countries;
|
•
|
the impact of Brexit on our operations, supply chain, regulatory approvals and personnel;
|
•
|
developments or disputes concerning patent applications, issued patents or other proprietary rights;
|
•
|
the recruitment or departure of key personnel;
|
•
|
the level of expenses related to our product or any of our product candidates or clinical development programs;
|
•
|
actual or anticipated variations in our quarterly operating results;
|
•
|
the number and characteristics of our efforts to in-license or acquire additional product candidates or products;
|
•
|
introduction of new products or services by us or our competitors;
|
•
|
failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;
|
•
|
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
|
•
|
variations in our financial results or those of companies that are perceived to be similar to us;
|
•
|
fluctuations in the valuation of companies perceived by investors to be comparable to us;
|
•
|
share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
|
•
|
announcement or expectation of additional financing efforts;
|
•
|
sales of our common stock by us, our insiders or our other stockholders;
|
•
|
changes in accounting practices;
|
•
|
lawsuits and other claims asserted against us;
|
•
|
changes in the structure of healthcare payment systems;
|
•
|
market conditions in the pharmaceutical and biotechnology sectors;
|
•
|
general economic, industry and market conditions;
|
•
|
publication of research reports about us, our competitors or our industry, or positive or negative recommendations or withdrawal of research coverage by securities or industry analysts;
|
•
|
other events or factors, many of which are beyond our control; and
|
•
|
the other factors described in this "Risk Factors" section.
|
•
|
a limited availability of market quotations for our securities;
|
•
|
reduced liquidity with respect to our securities;
|
•
|
a determination that our shares are a "penny stock," which will require brokers trading in our shares to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares;
|
•
|
a limited amount of news and analyst coverage for our company; and
|
•
|
a decreased ability to issue additional securities or obtain additional financing in the future.
|
Location
|
Approximate
Square Feet
|
|
Use
|
|
Lease expiry date
|
|
Cranbury, New Jersey, USA
|
90,000
|
|
|
Office and laboratory
|
|
September 2025
|
United Kingdom
|
46,617
|
|
|
Office
|
|
August 2028
|
Princeton, New Jersey, USA
|
21,922
|
|
|
Office
|
|
January 2022
|
|
High
|
|
Low
|
||||
2018
|
|
|
|
||||
First Quarter
|
$
|
17.12
|
|
|
$
|
13.76
|
|
Second Quarter
|
$
|
17.09
|
|
|
$
|
13.13
|
|
Third Quarter
|
$
|
16.54
|
|
|
$
|
11.60
|
|
Fourth Quarter
|
$
|
13.44
|
|
|
$
|
8.38
|
|
|
High
|
|
Low
|
||||
2017
|
|
|
|
||||
First Quarter
|
$
|
7.79
|
|
|
$
|
5.13
|
|
Second Quarter
|
$
|
10.44
|
|
|
$
|
6.65
|
|
Third Quarter
|
$
|
15.78
|
|
|
$
|
10.08
|
|
Fourth Quarter
|
$
|
16.24
|
|
|
$
|
12.51
|
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
|
2014
|
||||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
||||||||||
Net product sales
|
$
|
91,245
|
|
|
$
|
36,930
|
|
|
$
|
4,958
|
|
|
—
|
|
|
—
|
|
||
Research revenue
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,224
|
|
|||||
Total revenue
|
91,245
|
|
|
36,930
|
|
|
4,958
|
|
|
—
|
|
|
1,224
|
|
|||||
Total cost of goods sold
|
14,404
|
|
|
6,236
|
|
|
833
|
|
|
—
|
|
|
—
|
|
|||||
Gross profit
|
76,841
|
|
|
30,694
|
|
|
4,125
|
|
|
—
|
|
|
1,224
|
|
|||||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
||||||||||
Research and development
|
270,902
|
|
|
149,310
|
|
|
104,793
|
|
|
76,943
|
|
|
47,624
|
|
|||||
Selling, general and administrative
|
127,200
|
|
|
88,671
|
|
|
71,151
|
|
|
47,269
|
|
|
20,717
|
|
|||||
Changes in fair value of contingent consideration payable
|
3,300
|
|
|
(234,322
|
)
|
|
6,760
|
|
|
4,377
|
|
|
100
|
|
|||||
Loss on impairment of assets
|
—
|
|
|
465,427
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Restructuring charges
|
—
|
|
|
—
|
|
|
69
|
|
|
15
|
|
|
(63
|
)
|
|||||
Depreciation and amortization
|
4,216
|
|
|
3,593
|
|
|
3,242
|
|
|
1,833
|
|
|
1,547
|
|
|||||
Total operating expenses
|
405,618
|
|
|
472,679
|
|
|
186,015
|
|
|
130,437
|
|
|
69,925
|
|
|||||
Loss from operations
|
(328,777
|
)
|
|
(441,985
|
)
|
|
(181,890
|
)
|
|
(130,437
|
)
|
|
(68,701
|
)
|
|||||
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Interest income
|
10,461
|
|
|
4,096
|
|
|
1,602
|
|
|
929
|
|
|
223
|
|
|||||
Interest expense
|
(22,402
|
)
|
|
(17,240
|
)
|
|
(5,398
|
)
|
|
(1,578
|
)
|
|
(1,484
|
)
|
|||||
Change in fair value of derivatives
|
(2,739
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Loss on extinguishment of debt
|
—
|
|
|
—
|
|
|
(13,302
|
)
|
|
(952
|
)
|
|
—
|
|
|||||
Other income (expense)
|
(5,632
|
)
|
|
6,008
|
|
|
(4,793
|
)
|
|
(80
|
)
|
|
(77
|
)
|
|||||
Loss before income tax
|
(349,089
|
)
|
|
(449,121
|
)
|
|
(203,781
|
)
|
|
(132,118
|
)
|
|
(70,039
|
)
|
|||||
Income tax benefit
|
94
|
|
|
165,119
|
|
|
3,739
|
|
|
—
|
|
|
1,113
|
|
|||||
Net loss attributable to common stockholders
|
$
|
(348,995
|
)
|
|
$
|
(284,002
|
)
|
|
$
|
(200,042
|
)
|
|
$
|
(132,118
|
)
|
|
$
|
(68,926
|
)
|
Net loss attributable to common stockholders per common share — basic and diluted
|
$
|
(1.88
|
)
|
|
$
|
(1.85
|
)
|
|
$
|
(1.49
|
)
|
|
$
|
(1.20
|
)
|
|
$
|
(0.93
|
)
|
Weighted-average common shares outstanding — basic and diluted
|
185,790
|
|
|
153,355
|
|
|
134,402
|
|
|
109,924
|
|
|
74,444
|
|
|
As of December 31,
|
||||||||||||||||||
|
2018
|
|
2017
|
|
2016
|
|
2015
|
|
2014
|
||||||||||
Cash and cash equivalents and marketable securities
|
$
|
504,152
|
|
|
$
|
358,562
|
|
|
$
|
330,351
|
|
|
$
|
214,033
|
|
|
$
|
169,139
|
|
Working capital
|
464,971
|
|
|
321,925
|
|
|
229,105
|
|
|
142,985
|
|
|
134,392
|
|
|||||
Total assets
|
789,951
|
|
|
627,024
|
|
|
1,036,845
|
|
|
908,384
|
|
|
209,967
|
|
|||||
Total liabilities
|
447,039
|
|
|
274,174
|
|
|
676,694
|
|
|
560,550
|
|
|
87,789
|
|
|||||
Accumulated deficit
|
(1,412,222
|
)
|
|
(1,063,610
|
)
|
|
(779,608
|
)
|
|
(579,566
|
)
|
|
(447,448
|
)
|
|||||
Total stockholders' equity
|
342,912
|
|
|
352,850
|
|
|
360,151
|
|
|
347,834
|
|
|
122,178
|
|
|
|
Years Ended December 31,
|
||||||||||
(in thousands)
|
|
2018
|
|
2017
|
|
Change
|
||||||
Net product sales
|
|
$
|
91,245
|
|
|
$
|
36,930
|
|
|
$
|
54,315
|
|
Cost of goods sold
|
|
14,404
|
|
|
6,236
|
|
|
8,168
|
|
|||
Cost of goods sold as a percentage of net product sales
|
|
15.8
|
%
|
|
16.9
|
%
|
|
(1.1
|
)%
|
|||
Operating expenses:
|
|
|
|
|
|
|
||||||
Research and development
|
|
270,902
|
|
|
149,310
|
|
|
121,592
|
|
|||
Selling, general and administrative
|
|
127,200
|
|
|
88,671
|
|
|
38,529
|
|
|||
Changes in fair value of contingent consideration payable
|
|
3,300
|
|
|
(234,322
|
)
|
|
237,622
|
|
|||
Loss on impairment of asset
|
|
—
|
|
|
465,427
|
|
|
(465,427
|
)
|
|||
Depreciation
|
|
4,216
|
|
|
3,593
|
|
|
623
|
|
|||
Other income (expense):
|
|
|
|
|
|
|
||||||
Interest income
|
|
10,461
|
|
|
4,096
|
|
|
6,365
|
|
|||
Interest expense
|
|
(22,402
|
)
|
|
(17,240
|
)
|
|
(5,162
|
)
|
|||
Change in fair value of derivatives
|
|
(2,739
|
)
|
|
—
|
|
|
(2,739
|
)
|
|||
Other (expense) income
|
|
(5,632
|
)
|
|
6,008
|
|
|
(11,640
|
)
|
|||
Income tax benefit
|
|
94
|
|
|
165,119
|
|
|
(165,025
|
)
|
|||
Net loss attributable to common stockholders
|
|
$
|
(348,995
|
)
|
|
$
|
(284,002
|
)
|
|
$
|
(64,993
|
)
|
(in thousands)
|
|
Years Ended December 31,
|
||||||
Projects
|
|
2018
|
|
2017
|
||||
Third party direct project expenses
|
|
|
|
|
|
|
||
Migalastat (Fabry Disease)
|
|
$
|
12,665
|
|
|
$
|
11,107
|
|
AT-GAA (Pompe Disease)
|
|
55,919
|
|
|
49,890
|
|
||
SD-101 (EB-Epidermolysis Bullosa)
|
|
337
|
|
|
15,424
|
|
||
Gene therapy programs
|
|
137
|
|
|
—
|
|
||
Pre-clinical programs
|
|
1,225
|
|
|
539
|
|
||
Total third party direct project expenses
|
|
70,283
|
|
|
76,960
|
|
||
Other project costs
|
|
|
|
|
|
|
||
Personnel costs
|
|
62,999
|
|
|
50,095
|
|
||
Other costs
|
|
30,620
|
|
|
22,255
|
|
||
Total other project costs
|
|
93,619
|
|
|
72,350
|
|
||
Business development transactions
|
|
107,000
|
|
|
—
|
|
||
Total research and development costs
|
|
$
|
270,902
|
|
|
$
|
149,310
|
|
|
|
Years Ended December 31,
|
|||||||||
(in thousands)
|
|
2017
|
|
2016
|
|
Change
|
|||||
Net product sales
|
|
$
|
36,930
|
|
|
4,958
|
|
|
$
|
31,972
|
|
Cost of goods sold
|
|
6,236
|
|
|
833
|
|
|
5,403
|
|
||
Cost of goods sold as a percentage of net product sales
|
|
16.9
|
%
|
|
16.8
|
%
|
|
0.1
|
%
|
||
Operating expenses:
|
|
|
|
|
|
|
|||||
Research and development
|
|
149,310
|
|
|
104,793
|
|
|
44,517
|
|
||
Selling, general and administrative
|
|
88,671
|
|
|
71,151
|
|
|
17,520
|
|
||
Changes in fair value of contingent consideration payable
|
|
(234,322
|
)
|
|
6,760
|
|
|
(241,082
|
)
|
||
Loss on impairment of asset
|
|
465,427
|
|
|
—
|
|
|
465,427
|
|
||
Restructuring charges
|
|
—
|
|
|
69
|
|
|
(69
|
)
|
||
Depreciation
|
|
3,593
|
|
|
3,242
|
|
|
351
|
|
||
Other income (expense):
|
|
|
|
|
|
|
|||||
Interest income
|
|
4,096
|
|
|
1,602
|
|
|
2,494
|
|
||
Interest expense
|
|
(17,240
|
)
|
|
(5,398
|
)
|
|
(11,842
|
)
|
||
Change in fair value of derivatives
|
|
—
|
|
|
(13,302
|
)
|
|
13,302
|
|
||
Other income (expense)
|
|
6,008
|
|
|
(4,793
|
)
|
|
10,801
|
|
||
Income tax benefit
|
|
165,119
|
|
|
3,739
|
|
|
161,380
|
|
||
Net loss attributable to common stockholders
|
|
(284,002
|
)
|
|
(200,042
|
)
|
|
(83,960
|
)
|
(in thousands)
|
|
Years Ended December 31,
|
||||||
Projects
|
|
2017
|
|
2016
|
||||
Third party direct project expenses
|
|
|
|
|
|
|
||
Migalastat (Fabry Disease)
|
|
$
|
11,107
|
|
|
$
|
14,055
|
|
AT-GAA (Pompe Disease)
|
|
49,890
|
|
|
20,548
|
|
||
SD-101 (EB-Epidermolysis Bullosa)
|
|
15,424
|
|
|
9,530
|
|
||
Pre-clinical programs
|
|
539
|
|
|
6,939
|
|
||
Total third party direct project expenses
|
|
76,960
|
|
|
51,072
|
|
||
Other project costs
|
|
|
|
|
||||
Personnel costs
|
|
50,095
|
|
|
36,624
|
|
||
Other costs
|
|
22,255
|
|
|
17,097
|
|
||
Total other project costs
|
|
72,350
|
|
|
53,721
|
|
||
Total research and development costs
|
|
$
|
149,310
|
|
|
$
|
104,793
|
|
•
|
internal costs associated with our research and clinical development activities;
|
•
|
payments we make to third party contract research organizations, contract manufacturers, investigative sites, and consultants;
|
•
|
technology license costs;
|
•
|
manufacturing development costs;
|
•
|
personnel-related expenses, including salaries, benefits, travel, and related costs for the personnel involved in drug discovery and development;
|
•
|
activities relating to regulatory filings and the advancement of our product candidates through preclinical studies and clinical trials; and
|
•
|
facilities and other allocated expenses, which include direct and allocated expenses for rent, facility maintenance, as well as laboratory and other supplies.
|
•
|
the number of clinical sites included in the trials;
|
•
|
the length of time required to enroll suitable patients;
|
•
|
the number of patients that ultimately participate in the trials;
|
•
|
the results of our clinical trials; and
|
•
|
any mandate by the FDA or other regulatory authority to conduct clinical trials beyond those currently anticipated.
|
•
|
the feasibility and timing of achievement of development, regulatory and commercial milestones;
|
•
|
expected costs to develop the in-process research and development into commercially viable products; and
|
•
|
future expected cash flows from product sales.
|
•
|
fees owed to contract research organizations in connection with preclinical, toxicology studies and clinical trials;
|
•
|
fees owed to investigative sites in connection with clinical trials;
|
•
|
fees owed to contract manufacturers in connection with the production of clinical trial materials;
|
•
|
fees owed for professional services, and
|
•
|
unpaid salaries, wages and benefits.
|
•
|
the progress and results of our preclinical and clinical trials of our drug candidates;
|
•
|
the cost of manufacturing drug supply for our clinical and preclinical studies, including the significant cost of manufacturing Pompe ERT and gene therapies;
|
•
|
the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates including those testing the use of pharmacological chaperones co-formulated and co-administered with ERT and for the treatment of LSDs and gene therapies for the treatment of rare genetic metabolic diseases;
|
•
|
the future results of on-going preclinical research and subsequent clinical trials for CDD, including our ability to obtain regulatory approvals and commercialize CDKL5 therapies and obtain market acceptance for such therapies;
|
•
|
the costs, timing and outcome of regulatory review of our product candidates;
|
•
|
the number and development requirements of other product candidates that we pursue;
|
•
|
the costs of commercialization activities, including product marketing, sales and distribution;
|
•
|
the emergence of competing technologies and other adverse market developments;
|
•
|
our ability to successfully commercialize Galafold
®
(“migalastat HCl”);
|
•
|
our ability to manufacture or supply sufficient clinical or commercial products;
|
•
|
our ability to obtain reimbursement for Galafold
®
;
|
•
|
our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold
®
;
|
•
|
our ability to obtain market acceptance of Galafold
®
;
|
•
|
the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;
|
•
|
the extent to which we acquire or invest in businesses, products and technologies;
|
•
|
our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;
|
•
|
our ability to establish collaborations and obtain milestone, royalty or other payments from any such collaborators;
|
•
|
our ability to adjust to changes in European and United Kingdom markets as the United Kingdom leaves the European Union; and
|
•
|
fluctuations in foreign currency exchange rates; and changes in accounting standards.
|
(in thousands)
|
Total
|
|
Less than 1 year
|
|
1-3 years
|
|
3-5 years
|
|
Over 5 years
|
||||||||||
Operating lease obligations
(2)
|
$
|
30,887
|
|
|
$
|
6,244
|
|
|
$
|
7,623
|
|
|
$
|
6,982
|
|
|
$
|
10,038
|
|
Capital lease obligations, including interest
(3)
|
331
|
|
|
194
|
|
|
107
|
|
|
30
|
|
|
—
|
|
|||||
Debt obligations, including interest
(4)
|
508,067
|
|
|
22,430
|
|
|
45,149
|
|
|
440,488
|
|
|
—
|
|
|||||
Purchase obligations
(5)
|
47,287
|
|
|
47,287
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Total fixed contractual obligations
(1)
|
$
|
586,572
|
|
|
$
|
76,155
|
|
|
$
|
52,879
|
|
|
$
|
447,500
|
|
|
$
|
10,038
|
|
(1)
|
This table does not include (a) any milestone payments which may become payable to third parties under license agreements as the timing and likelihood of such payments are not known, (b) any royalty payments to third parties as the amounts of such payments, timing and/or the likelihood of such payments are not known, (c) amounts, if any, that may be committed in the future to construct additional facilities, (d) agreements with clinical research organizations and other outside contractors who are partially responsible for conducting and monitoring our clinical trials for our drug candidates including Galafold
®
. These contractual obligations are not reflected in the table above because we may terminate them without penalty, and (e) contracts that are entered into in the ordinary course of business which are not material in the aggregate in any period presented above.
|
(2)
|
Represents the future payments on operating leases for properties, equipment and vehicles at the United States and international locations. For more details, refer to "— Note 13. Leases," in our Notes to Consolidated Financial Statements.
|
(3)
|
Represents the future payments of principal and interest to be made on our capital leases. For more details, refer to "— Note 13. Leases," in our Notes to Consolidated Financial Statements.
|
(4)
|
Represents the future payments of principal and interest to be made on our $250 million 3% unsecured Convertible Notes due 2023 (the "Convertible Notes") and our $150 million Secured Senior Term Loan due 2023 (“Senior Secured Term Loan”). The Convertible Notes bear interest at a fixed rate of 3.00% per year, payable semiannually on June 15 and December 15 of each year, beginning on June 15, 2017 and will mature on December 15, 2023. The Senior Secured Term Loan bears interest at a rate equal to the 3-month LIBOR plus 7.5% per year, payable quarterly of each year, beginning on December 31, 2019 and will mature on September 28, 2023. In the first quarter of 2019, we converted a portion of the Convertible Notes into equity. For more details, refer to "— Note 12. Debt," in our Notes to Consolidated Financial Statements.
|
(5)
|
Represent minimum purchase commitments due to third parties. Contracts for which our commitment is variable, based on volumes, with no fixed minimum quantities, and contracts that can be canceled without payment penalties have been excluded. The purchase obligations included above are in addition to amounts included in total recorded on our December 31, 2018 consolidated balance sheet.
|
•
|
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of Amicus Therapeutics, Inc.;
|
•
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of Amicus therapeutics, Inc. are being made only in accordance with authorizations of management and directors of Amicus therapeutics, Inc.; and
|
•
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of Amicus Therapeutics, Inc. that could have a material effect on the financial statements.
|
/s/ JOHN F. CROWLEY
|
|
/s/ DAPHNE QUIMI
|
Chairman and Chief Executive Officer
|
|
Chief Financial Officer
|
/s/ Ernst & Young LLP
|
/s/ Ernst & Young LLP
|
|
December 31,
|
||||||
|
2018
|
|
2017
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
79,749
|
|
|
$
|
49,060
|
|
Investments in marketable securities
|
424,403
|
|
|
309,502
|
|
||
Accounts receivable
|
21,962
|
|
|
9,464
|
|
||
Inventories
|
8,390
|
|
|
4,623
|
|
||
Prepaid expenses and other current assets
|
16,592
|
|
|
19,316
|
|
||
Total current assets
|
551,096
|
|
|
391,965
|
|
||
Property and equipment, less accumulated depreciation of $15,671 and $12,515 at December 31, 2018 and 2017, respectively
|
11,375
|
|
|
9,062
|
|
||
In-process research & development
|
23,000
|
|
|
23,000
|
|
||
Goodwill
|
197,797
|
|
|
197,797
|
|
||
Other non-current assets
|
6,683
|
|
|
5,200
|
|
||
Total Assets
|
$
|
789,951
|
|
|
$
|
627,024
|
|
Liabilities and Stockholders' Equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable, accrued expenses, and other current liabilities
|
$
|
80,625
|
|
|
$
|
53,890
|
|
Deferred reimbursements
|
5,500
|
|
|
7,750
|
|
||
Contingent consideration payable
|
—
|
|
|
8,400
|
|
||
Total current liabilities
|
86,125
|
|
|
70,040
|
|
||
Deferred reimbursements
|
10,156
|
|
|
14,156
|
|
||
Convertible notes
|
175,006
|
|
|
164,167
|
|
||
Senior secured term loan
|
146,734
|
|
|
—
|
|
||
Contingent consideration payable
|
19,700
|
|
|
17,000
|
|
||
Deferred income taxes
|
6,465
|
|
|
6,465
|
|
||
Other non-current liabilities
|
2,853
|
|
|
2,346
|
|
||
Total Liabilities
|
447,039
|
|
|
274,174
|
|
||
Commitments and contingencies
|
|
|
|
||||
Stockholders' equity:
|
|
|
|
||||
Common stock, $.01 par value, 500,000,000 shares authorized, 189,383,924 shares issued and outstanding at December 31, 2018 Common stock, $.01 par value, 250,000,000 shares authorized, 166,989,790 shares issued and outstanding at December 31, 2017
|
1,942
|
|
|
1,721
|
|
||
Additional paid-in capital
|
1,740,061
|
|
|
1,400,758
|
|
||
Accumulated other comprehensive loss:
|
|
|
|
||||
Foreign currency translation adjustment
|
495
|
|
|
(1,659
|
)
|
||
Unrealized loss on available-for securities
|
(427
|
)
|
|
(436
|
)
|
||
Warrants
|
13,063
|
|
|
16,076
|
|
||
Accumulated deficit
|
(1,412,222
|
)
|
|
(1,063,610
|
)
|
||
Total stockholders' equity
|
342,912
|
|
|
352,850
|
|
||
Total Liabilities and Stockholders' Equity
|
$
|
789,951
|
|
|
$
|
627,024
|
|
|
Years Ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Revenue:
|
|
|
|
|
|
||||||
Net product sales
|
$
|
91,245
|
|
|
$
|
36,930
|
|
|
$
|
4,958
|
|
Cost of goods sold
|
14,404
|
|
|
6,236
|
|
|
833
|
|
|||
Gross profit
|
76,841
|
|
|
30,694
|
|
|
4,125
|
|
|||
Operating expenses:
|
|
|
|
|
|
||||||
Research and development
|
270,902
|
|
|
149,310
|
|
|
104,793
|
|
|||
Selling, general and administrative
|
127,200
|
|
|
88,671
|
|
|
71,151
|
|
|||
Changes in fair value of contingent consideration payable
|
3,300
|
|
|
(234,322
|
)
|
|
6,760
|
|
|||
Loss on impairment of assets
|
—
|
|
|
465,427
|
|
|
—
|
|
|||
Restructuring charges
|
—
|
|
|
—
|
|
|
69
|
|
|||
Depreciation
|
4,216
|
|
|
3,593
|
|
|
3,242
|
|
|||
Total operating expenses
|
405,618
|
|
|
472,679
|
|
|
186,015
|
|
|||
Loss from operations
|
(328,777
|
)
|
|
(441,985
|
)
|
|
(181,890
|
)
|
|||
Other income (expenses):
|
|
|
|
|
|
||||||
Interest income
|
10,461
|
|
|
4,096
|
|
|
1,602
|
|
|||
Interest expense
|
(22,402
|
)
|
|
(17,240
|
)
|
|
(5,398
|
)
|
|||
Change in fair value of derivatives
|
(2,739
|
)
|
|
—
|
|
|
—
|
|
|||
Loss on extinguishment of debt
|
—
|
|
|
—
|
|
|
(13,302
|
)
|
|||
Other income (expense)
|
(5,632
|
)
|
|
6,008
|
|
|
(4,793
|
)
|
|||
Loss before income tax
|
(349,089
|
)
|
|
(449,121
|
)
|
|
(203,781
|
)
|
|||
Income tax benefit
|
94
|
|
|
165,119
|
|
|
3,739
|
|
|||
Net loss attributable to common stockholders
|
$
|
(348,995
|
)
|
|
$
|
(284,002
|
)
|
|
$
|
(200,042
|
)
|
Net loss attributable to common stockholders per common share — basic and diluted
|
$
|
(1.88
|
)
|
|
$
|
(1.85
|
)
|
|
$
|
(1.49
|
)
|
Weighted-average common shares outstanding — basic and diluted
|
185,790,021
|
|
|
153,355,144
|
|
|
134,401,588
|
|
|
Years Ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Net loss
|
$
|
(348,995
|
)
|
|
$
|
(284,002
|
)
|
|
$
|
(200,042
|
)
|
Other comprehensive gain (loss):
|
|
|
|
|
|
||||||
Foreign currency translation adjustment gain (loss), net of tax impact of $0, $0, $0, respectively
|
2,537
|
|
|
(3,604
|
)
|
|
1,945
|
|
|||
Unrealized gain (loss) on available-for-sale securities
|
9
|
|
|
(538
|
)
|
|
217
|
|
|||
Other comprehensive income (loss)
|
2,546
|
|
|
(4,142
|
)
|
|
2,162
|
|
|||
Comprehensive loss
|
$
|
(346,449
|
)
|
|
$
|
(288,144
|
)
|
|
$
|
(197,880
|
)
|
|
Common Stock
|
|
Additional
Paid-In Capital |
|
Warrants
|
|
Other
Comprehensive Gain (Loss) |
|
Accumulated
Deficit |
|
Total
Stockholders' Equity |
|||||||||||||||
|
Shares
|
|
Amount
|
|
|
|
|
|
||||||||||||||||||
Balance at December 31, 2015
|
125,027,034
|
|
|
1,306
|
|
|
917,454
|
|
|
8,755
|
|
|
(115
|
)
|
|
(579,566
|
)
|
|
347,834
|
|
||||||
Stock issued from exercise of stock options, net
|
723,102
|
|
|
7
|
|
|
3,029
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,036
|
|
||||||
Stock issued from ATM transactions
|
14,989,027
|
|
|
150
|
|
|
96,918
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
97,068
|
|
||||||
Stock issued for MiaMed acquisition
|
825,603
|
|
|
8
|
|
|
4,599
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4,607
|
|
||||||
Restricted stock tax vesting
|
268,425
|
|
|
—
|
|
|
(1,282
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,282
|
)
|
||||||
Stock issued for contingent consideration
|
858,795
|
|
|
9
|
|
|
6,106
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6,115
|
|
||||||
Receivable from investor
|
—
|
|
|
—
|
|
|
932
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
932
|
|
||||||
Warrants issued in debt financing
|
—
|
|
|
—
|
|
|
—
|
|
|
7,321
|
|
|
—
|
|
|
—
|
|
|
7,321
|
|
||||||
Equity component of the Convertible Notes issuance, net of issuance costs of $2,709
|
—
|
|
|
—
|
|
|
88,346
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
88,346
|
|
||||||
Premium paid for Capped Call Confirmations
|
|
|
|
|
(13,450
|
)
|
|
—
|
|
|
|
|
|
|
(13,450
|
)
|
||||||||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
17,504
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
17,504
|
|
||||||
Unrealized holding gain on available-for-sale securities
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
217
|
|
|
—
|
|
|
217
|
|
||||||
Foreign currency translation adjustment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,945
|
|
|
—
|
|
|
1,945
|
|
||||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(200,042
|
)
|
|
(200,042
|
)
|
||||||
Balance at December 31, 2016
|
142,691,986
|
|
|
1,480
|
|
|
1,120,156
|
|
|
16,076
|
|
|
2,047
|
|
|
(779,608
|
)
|
|
360,151
|
|
||||||
Stock issued from exercise of stock options, net
|
2,878,681
|
|
|
29
|
|
|
16,272
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
16,301
|
|
||||||
Stock issued from equity financing
|
21,122,449
|
|
|
212
|
|
|
242,825
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
243,037
|
|
||||||
Restricted stock tax vesting
|
296,674
|
|
|
—
|
|
|
(1,596
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,596
|
)
|
||||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
23,101
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
23,101
|
|
||||||
Unrealized holding gain on available-for-sale securities
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(538
|
)
|
|
—
|
|
|
(538
|
)
|
||||||
Foreign currency translation adjustment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(3,604
|
)
|
|
—
|
|
|
(3,604
|
)
|
||||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(284,002
|
)
|
|
(284,002
|
)
|
||||||
Balance at December 31, 2017
|
166,989,790
|
|
|
1,721
|
|
|
1,400,758
|
|
|
16,076
|
|
|
(2,095
|
)
|
|
(1,063,610
|
)
|
|
352,850
|
|
||||||
Stock issued from exercise of stock options, net
|
1,397,908
|
|
|
14
|
|
|
9,130
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
9,144
|
|
||||||
Stock issued from equity financing
|
20,239,839
|
|
|
202
|
|
|
294,381
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
294,583
|
|
||||||
Restricted stock tax vesting
|
303,173
|
|
|
—
|
|
|
(2,832
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2,832
|
)
|
||||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
29,260
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
29,260
|
|
||||||
Reclassification upon ASU 2018-02 adoption
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(383
|
)
|
|
383
|
|
|
—
|
|
||||||
Warrants exercised
|
453,214
|
|
|
5
|
|
|
6,625
|
|
|
(3,013
|
)
|
|
—
|
|
|
—
|
|
|
3,617
|
|
||||||
Change in fair value of derivatives
|
—
|
|
|
—
|
|
|
2,739
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,739
|
|
||||||
Unrealized holding gain on available-for-sale securities
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
9
|
|
|
—
|
|
|
9
|
|
||||||
Foreign currency translation adjustment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,537
|
|
|
—
|
|
|
2,537
|
|
||||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(348,995
|
)
|
|
(348,995
|
)
|
||||||
Balance at December 31, 2018
|
189,383,924
|
|
|
$
|
1,942
|
|
|
$
|
1,740,061
|
|
|
$
|
13,063
|
|
|
$
|
68
|
|
|
$
|
(1,412,222
|
)
|
|
$
|
342,912
|
|
|
Years Ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Operating activities
|
|
|
|
|
|
||||||
Net loss
|
$
|
(348,995
|
)
|
|
$
|
(284,002
|
)
|
|
$
|
(200,042
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
||||||
Amortization of debt discount and deferred financing
|
10,976
|
|
|
9,703
|
|
|
2,689
|
|
|||
Depreciation
|
4,216
|
|
|
3,593
|
|
|
3,242
|
|
|||
Stock-based compensation
|
29,260
|
|
|
23,101
|
|
|
17,504
|
|
|||
Restructuring charges
|
—
|
|
|
—
|
|
|
69
|
|
|||
Change in fair value of derivatives
|
2,739
|
|
|
(265
|
)
|
|
265
|
|
|||
Non-cash changes in the fair value of contingent consideration payable
|
3,300
|
|
|
(234,322
|
)
|
|
6,760
|
|
|||
Charges to research expense for stock issued in asset acquisition
|
—
|
|
|
—
|
|
|
4,607
|
|
|||
Loss on extinguishment of debt
|
—
|
|
|
—
|
|
|
13,302
|
|
|||
Foreign currency remeasurement (gain) loss
|
3,217
|
|
|
(5,620
|
)
|
|
3,660
|
|
|||
Non-cash deferred taxes
|
—
|
|
|
(167,305
|
)
|
|
(3,742
|
)
|
|||
(Gain) loss on disposal of assets
|
59
|
|
|
(8
|
)
|
|
17
|
|
|||
Loss on impairment
|
—
|
|
|
465,427
|
|
|
—
|
|
|||
Changes in operating assets and liabilities:
|
|
|
|
|
|
||||||
Accounts receivable
|
(13,294
|
)
|
|
(7,725
|
)
|
|
(1,419
|
)
|
|||
Inventories
|
(4,205
|
)
|
|
(897
|
)
|
|
(3,651
|
)
|
|||
Prepaid expenses and other current assets
|
2,488
|
|
|
(15,329
|
)
|
|
(394
|
)
|
|||
Other non-current assets
|
(1,039
|
)
|
|
(729
|
)
|
|
(970
|
)
|
|||
Account payable and accrued expenses
|
17,115
|
|
|
12,563
|
|
|
7,131
|
|
|||
Non-current liabilities
|
458
|
|
|
720
|
|
|
825
|
|
|||
Deferred reimbursements
|
(6,250
|
)
|
|
(12,600
|
)
|
|
—
|
|
|||
Net cash used in operating activities
|
(299,955
|
)
|
|
(213,695
|
)
|
|
(150,147
|
)
|
|||
Investing activities
|
|
|
|
|
|
||||||
Sale and redemption of marketable securities
|
463,502
|
|
|
323,753
|
|
|
221,374
|
|
|||
Purchases of marketable securities
|
(578,394
|
)
|
|
(490,468
|
)
|
|
(219,932
|
)
|
|||
Capital expenditures
|
(6,308
|
)
|
|
(4,526
|
)
|
|
(5,951
|
)
|
|||
Net cash used in investing activities
|
(121,200
|
)
|
|
(171,241
|
)
|
|
(4,509
|
)
|
|||
Financing activities
|
|
|
|
|
|
||||||
Proceeds from issuance of common stock and warrants, net of issuance costs
|
294,584
|
|
|
243,037
|
|
|
97,068
|
|
|||
Payments of secured loan agreement
|
—
|
|
|
—
|
|
|
(80,000
|
)
|
|||
Payment of capital leases
|
(334
|
)
|
|
(308
|
)
|
|
(193
|
)
|
|||
Purchase of vested restricted stock units
|
(2,832
|
)
|
|
(1,596
|
)
|
|
(1,282
|
)
|
|||
Proceeds from exercise of stock options
|
9,144
|
|
|
16,301
|
|
|
3,036
|
|
|||
Proceeds from exercise of warrants
|
3,617
|
|
|
—
|
|
|
—
|
|
|||
Payment of contingent consideration
|
—
|
|
|
(10,000
|
)
|
|
(5,000
|
)
|
|||
Proceeds from issuance of convertible notes, net of issuance costs
|
—
|
|
|
—
|
|
|
242,536
|
|
|||
Premiums paid for Capped Call Confirmations
|
—
|
|
|
—
|
|
|
(13,450
|
)
|
|||
Proceeds from loan agreements, net of issuance costs
|
146,596
|
|
|
—
|
|
|
30,000
|
|
|||
Net cash provided by financing activities
|
450,775
|
|
|
247,434
|
|
|
272,715
|
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
1,518
|
|
|
1,326
|
|
|
(131
|
)
|
|||
Net increase (decrease) in cash and cash equivalents and restricted cash
|
31,138
|
|
|
(136,176
|
)
|
|
117,928
|
|
|||
Cash and cash equivalents and restricted cash at beginning of year/period
|
51,237
|
|
|
187,413
|
|
|
69,485
|
|
|||
Cash and cash equivalents and restricted cash at end of year/period
|
$
|
82,375
|
|
|
$
|
51,237
|
|
|
$
|
187,413
|
|
Supplemental disclosures of cash flow information
|
|
|
|
|
|
||||||
Cash paid during the period for interest
|
$
|
7,500
|
|
|
$
|
7,424
|
|
|
$
|
2,990
|
|
Contingent consideration paid in shares
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
6,115
|
|
Capital expenditures unpaid at the end of period
|
$
|
106
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Capital expenditures funded by capital lease borrowings
|
$
|
208
|
|
|
$
|
—
|
|
|
$
|
944
|
|
|
As of December 31, 2018
|
||||||||||||||
(in thousands)
|
Cost
|
|
Unrealized
Gain
|
|
Unrealized
Loss
|
|
Fair
Value
|
||||||||
Cash and cash equivalents
|
$
|
79,749
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
79,749
|
|
Corporate debt securities, current portion
|
240,969
|
|
|
7
|
|
|
(250
|
)
|
|
240,726
|
|
||||
Commercial paper
|
115,245
|
|
|
—
|
|
|
(104
|
)
|
|
115,141
|
|
||||
Asset-backed securities
|
68,215
|
|
|
4
|
|
|
(84
|
)
|
|
68,135
|
|
||||
Money market
|
350
|
|
|
—
|
|
|
—
|
|
|
350
|
|
||||
Certificate of deposit
|
51
|
|
|
—
|
|
|
—
|
|
|
51
|
|
||||
|
$
|
504,579
|
|
|
$
|
11
|
|
|
$
|
(438
|
)
|
|
$
|
504,152
|
|
Included in cash and cash equivalents
|
$
|
79,749
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
79,749
|
|
Included in marketable securities, current
|
424,830
|
|
|
11
|
|
|
(438
|
)
|
|
424,403
|
|
||||
Total cash, cash equivalents and marketable securities
|
$
|
504,579
|
|
|
$
|
11
|
|
|
$
|
(438
|
)
|
|
$
|
504,152
|
|
|
As of December 31, 2017
|
||||||||||||||
(in thousands)
|
Cost
|
|
Unrealized
Gain
|
|
Unrealized
Loss
|
|
Fair
Value
|
||||||||
Cash and cash equivalents
|
$
|
49,060
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
49,060
|
|
Corporate debt securities, current portion
|
199,314
|
|
|
1
|
|
|
(303
|
)
|
|
199,012
|
|
||||
Commercial paper
|
79,878
|
|
|
—
|
|
|
(75
|
)
|
|
79,803
|
|
||||
Asset-backed securities
|
30,346
|
|
|
—
|
|
|
(59
|
)
|
|
30,287
|
|
||||
Money market
|
350
|
|
|
—
|
|
|
—
|
|
|
350
|
|
||||
Certificate of deposit
|
50
|
|
|
—
|
|
|
—
|
|
|
50
|
|
||||
|
$
|
358,998
|
|
|
$
|
1
|
|
|
$
|
(437
|
)
|
|
$
|
358,562
|
|
Included in cash and cash equivalents
|
$
|
49,060
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
49,060
|
|
Included in marketable securities, current
|
309,938
|
|
|
1
|
|
|
(437
|
)
|
|
309,502
|
|
||||
Total cash, cash equivalents and marketable securities
|
$
|
358,998
|
|
|
$
|
1
|
|
|
$
|
(437
|
)
|
|
$
|
358,562
|
|
(in thousands)
|
|
December 31, 2018
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||
Cash and cash equivalents
|
|
$
|
79,749
|
|
|
$
|
49,060
|
|
|
$
|
187,026
|
|
Restricted cash
|
|
2,626
|
|
|
2,177
|
|
|
387
|
|
|||
Cash and cash equivalents and restricted cash shown in the statement of cash flows
|
|
$
|
82,375
|
|
|
$
|
51,237
|
|
|
$
|
187,413
|
|
(in thousands)
|
December 31, 2018
|
|
December 31, 2017
|
||||
Raw materials
|
$
|
1,291
|
|
|
$
|
2,393
|
|
Work-in-process
|
3,485
|
|
|
1,450
|
|
||
Finished goods
|
3,614
|
|
|
780
|
|
||
Total inventories
|
$
|
8,390
|
|
|
$
|
4,623
|
|
|
December 31,
|
||||||
(in thousands)
|
2018
|
|
2017
|
||||
Property and equipment consist of the following:
|
|
|
|
||||
Computer equipment
|
$
|
4,691
|
|
|
$
|
3,746
|
|
Computer software
|
1,298
|
|
|
1,236
|
|
||
Research equipment
|
8,445
|
|
|
6,379
|
|
||
Furniture and fixtures
|
4,876
|
|
|
2,992
|
|
||
Leasehold improvements
|
7,425
|
|
|
7,193
|
|
||
Vehicles
|
209
|
|
|
—
|
|
||
Construction in progress
|
102
|
|
|
31
|
|
||
Gross property and equipment
|
27,046
|
|
|
21,577
|
|
||
Less accumulated depreciation
|
(15,671
|
)
|
|
(12,515
|
)
|
||
Net property and equipment
|
$
|
11,375
|
|
|
$
|
9,062
|
|
|
December 31,
|
||||||
(in thousands)
|
2018
|
|
2017
|
||||
Accounts payable
|
$
|
6,606
|
|
|
$
|
7,867
|
|
Accrued professional fees
|
2,276
|
|
|
5,845
|
|
||
Accrued contract manufacturing & contract research costs
|
5,890
|
|
|
4,632
|
|
||
Accrued compensation and benefits
|
21,731
|
|
|
19,620
|
|
||
Accrued facility costs
|
2,102
|
|
|
1,665
|
|
||
Accrued program fees
|
16,674
|
|
|
5,707
|
|
||
Royalties payable
|
4,463
|
|
|
2,529
|
|
||
Accrued interest
|
4,189
|
|
|
313
|
|
||
Milestone payments
|
9,000
|
|
|
—
|
|
||
Accrued sales rebates and discounts
|
3,636
|
|
|
1,957
|
|
||
Other
|
4,058
|
|
|
3,755
|
|
||
|
$
|
80,625
|
|
|
$
|
53,890
|
|
|
Years Ended
December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Expected stock price volatility
|
78.6
|
%
|
|
82.8
|
%
|
|
81.3
|
%
|
|||
Risk free interest rate
|
2.4
|
%
|
|
2.0
|
%
|
|
1.5
|
%
|
|||
Expected life of options (years)
|
5.62
|
|
|
6.18
|
|
|
6.25
|
|
|||
Expected annual dividend per share
|
$
|
0.00
|
|
|
$
|
0.00
|
|
|
$
|
0.00
|
|
|
Number of
Shares
|
|
Weighted
Average
Exercise
Price
|
|
Weighted
Average
Remaining
Contractual
Life
|
|
Aggregate
Intrinsic
Value
|
|||||
|
(in thousands)
|
|
|
|
|
|
(in millions)
|
|||||
Options outstanding, December 31, 2015
|
11,729.2
|
|
|
$
|
7.11
|
|
|
|
|
|
||
Granted
|
5,114.1
|
|
|
$
|
7.67
|
|
|
|
|
|
||
Exercised
|
(723.1
|
)
|
|
$
|
4.20
|
|
|
|
|
|
||
Forfeited
|
(622.7
|
)
|
|
$
|
8.62
|
|
|
|
|
|
||
Options outstanding, December 31, 2016
|
15,497.5
|
|
|
$
|
7.37
|
|
|
|
|
|
||
Granted
|
3,695.3
|
|
|
$
|
7.17
|
|
|
|
|
|
||
Exercised
|
(2,878.7
|
)
|
|
$
|
5.67
|
|
|
|
|
|
||
Forfeited
|
(1,133.0
|
)
|
|
$
|
9.55
|
|
|
|
|
|
||
Options outstanding, December 31, 2017
|
15,181.1
|
|
|
$
|
7.48
|
|
|
|
|
|
||
Granted
|
2,348.0
|
|
|
$
|
14.96
|
|
|
|
|
|
||
Exercised
|
(1,398.0
|
)
|
|
$
|
6.54
|
|
|
|
|
|
||
Forfeited
|
(313.1
|
)
|
|
$
|
9.55
|
|
|
|
|
|
||
Expired
|
(8.0
|
)
|
|
10.76
|
|
|
|
|
||||
Options outstanding, December 31, 2018
|
15,810.0
|
|
|
$
|
8.63
|
|
|
6.7 years
|
|
$
|
37.6
|
|
Vested and unvested expected to vest, December 31, 2018
|
15,152.6
|
|
|
$
|
8.51
|
|
|
6.6 years
|
|
$
|
36.8
|
|
Exercisable at December 31, 2018
|
9,977.0
|
|
|
$
|
7.43
|
|
|
5.8 years
|
|
$
|
28.8
|
|
|
Number of
Share
|
|
Weighted
Average Grant
Date Fair
Value
|
|
Weighted
Average
Remaining
Years
|
|
Aggregate
Intrinsic
Value
|
|||||
|
(in thousands)
|
|
|
|
|
|
(in millions)
|
|||||
Non-vested units as of December 31, 2016
|
744.4
|
|
|
$
|
7.86
|
|
|
|
|
|
||
Granted
|
2,348.7
|
|
|
$
|
5.69
|
|
|
|
|
|
||
Vested
|
(318.2
|
)
|
|
$
|
9.23
|
|
|
|
|
|
||
Forfeited
|
(199.8
|
)
|
|
$
|
6.24
|
|
|
|
|
|
||
Non-vested units as of December 31, 2017
|
2,575.1
|
|
|
$
|
5.85
|
|
|
|
|
|
||
Granted
|
1,811.9
|
|
|
$
|
16.11
|
|
|
|
|
|
||
Vested
|
(530.0
|
)
|
|
$
|
6.01
|
|
|
|
|
|
||
Forfeited
|
(145.0
|
)
|
|
$
|
9.65
|
|
|
|
|
|
||
Non-vested units as of December 31, 2018
|
3,712.0
|
|
|
$
|
10.59
|
|
|
2.57
|
|
$
|
36.3
|
|
|
Years Ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Equity compensation expense recognized in:
|
|
|
|
|
|
||||||
Research and development expense
|
$
|
11,740
|
|
|
$
|
10,328
|
|
|
$
|
8,071
|
|
Selling, general and administrative expense
|
17,520
|
|
|
12,773
|
|
|
9,433
|
|
|||
Total equity compensation expense
|
$
|
29,260
|
|
|
$
|
23,101
|
|
|
$
|
17,504
|
|
(in thousands)
|
Level 2
|
|
Total
|
||||
Assets:
|
|
|
|
||||
Commercial paper
|
$
|
115,141
|
|
|
$
|
115,141
|
|
Asset-back securities
|
68,135
|
|
|
68,135
|
|
||
Corporate debt securities
|
240,726
|
|
|
240,726
|
|
||
Money market funds
|
3,082
|
|
|
3,082
|
|
||
|
$
|
427,084
|
|
|
$
|
427,084
|
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||
Liabilities:
|
|
|
|
|
|
||||||
Contingent consideration payable
|
$
|
—
|
|
|
$
|
19,700
|
|
|
$
|
19,700
|
|
Deferred compensation plan liability
|
2,732
|
|
|
—
|
|
|
2,732
|
|
|||
|
$
|
2,732
|
|
|
$
|
19,700
|
|
|
$
|
22,432
|
|
(in thousands)
|
Level 2
|
|
Total
|
||||
Assets:
|
|
|
|
||||
Commercial paper
|
$
|
79,803
|
|
|
$
|
79,803
|
|
Asset-back securities
|
30,287
|
|
|
30,287
|
|
||
Corporate debt securities
|
199,012
|
|
|
199,012
|
|
||
Money market funds
|
2,598
|
|
|
2,598
|
|
||
|
$
|
311,700
|
|
|
$
|
311,700
|
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||
Liabilities:
|
|
|
|
|
|
||||||
Contingent consideration payable
|
$
|
—
|
|
|
$
|
25,400
|
|
|
$
|
25,400
|
|
Deferred compensation plan liability
|
2,258
|
|
|
—
|
|
|
2,258
|
|
|||
|
$
|
2,258
|
|
|
$
|
25,400
|
|
|
$
|
27,658
|
|
Contingent Consideration Liability
|
|
Fair value as of
December 31, 2018 |
|
Valuation Technique
|
|
Unobservable Input
|
|
Range
|
|
|
|
|
|
|
Discount rate
|
|
10%
|
Clinical and regulatory milestones
|
|
$19.2 million
|
|
Probability weighted discounted cash flow
|
|
Probability of achievement of milestones
|
|
71.0% - 100.0%
|
|
|
|
|
|
|
Projected year of payments
|
|
2021 - 2022
|
|
Year ended December 31,
|
||||||
(in thousands)
|
2018
|
|
2017
|
||||
Balance, beginning of the period
|
$
|
25,400
|
|
|
$
|
269,722
|
|
Payment of contingent consideration in cash
|
—
|
|
|
(10,000
|
)
|
||
Milestone payable, included in accrued expenses
|
(9,000
|
)
|
|
—
|
|
||
Unrealized change in fair value change during the period, included in Statement of Operations
|
3,300
|
|
|
(234,322
|
)
|
||
Balance, end of the period
|
$
|
19,700
|
|
|
$
|
25,400
|
|
Liability component (in thousands)
|
2018
|
|
2017
|
||||
Principal
|
$
|
400,000
|
|
|
$
|
250,000
|
|
Less: debt discount
(1)
|
(74,145
|
)
|
|
(81,566
|
)
|
||
Less: deferred financing
(1)
|
(4,115
|
)
|
|
(4,267
|
)
|
||
Net carrying value of the debt
|
$
|
321,740
|
|
|
$
|
164,167
|
|
(1)
|
Included in the consolidated balance sheets within convertible notes and senior secured term loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.
|
Components (in thousands)
|
2018
|
|
2017
|
||||
Contractual interest expense
|
$
|
11,426
|
|
|
$
|
7,528
|
|
Amortization of deferred financing
|
555
|
|
|
470
|
|
||
Amortization of debt discount
|
10,421
|
|
|
9,241
|
|
||
Total
|
$
|
22,402
|
|
|
$
|
17,239
|
|
Effective interest rate of the liability component, convertible debt
|
10.85
|
%
|
|
10.85
|
%
|
||
Effective interest rate of the liability component, senior secured term loan
|
10.48
|
%
|
|
—
|
%
|
Location
|
Approximate
Square Feet
|
|
Use
|
|
Lease expiry date
|
|
Cranbury, New Jersey
|
90,000
|
|
|
Office and laboratory
|
|
September 2025
|
United Kingdom
|
46,617
|
|
|
Office
|
|
August 2028
|
Princeton, New Jersey
|
21,922
|
|
|
Office
|
|
January 2022
|
(in thousands)
|
2019
|
|
2020
|
|
2021
|
|
2022
|
|
2023 and
beyond |
|
Total
|
||||||||||||
Minimum lease payments
|
$
|
6,244
|
|
|
$
|
4,063
|
|
|
$
|
3,560
|
|
|
$
|
3,371
|
|
|
$
|
13,649
|
|
|
$
|
30,887
|
|
Years ending December 31:
|
|
||
2019
|
$
|
194
|
|
2020
|
60
|
|
|
2021
|
47
|
|
|
2022
|
30
|
|
|
2023 and beyond
|
—
|
|
|
Total principal obligation
|
$
|
331
|
|
(in thousands)
|
2018
|
|
2017
|
|
2016
|
||||||
Current
|
|
|
|
|
|
||||||
Federal
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
State
|
6
|
|
|
9
|
|
|
7
|
|
|||
Foreign
|
(100
|
)
|
|
2,276
|
|
|
—
|
|
|||
Deferred
|
|
|
|
|
|
||||||
Federal
|
—
|
|
|
(150,015
|
)
|
|
(1,101
|
)
|
|||
State
|
—
|
|
|
(17,389
|
)
|
|
(2,645
|
)
|
|||
Foreign
|
—
|
|
|
—
|
|
|
—
|
|
|||
Total
|
$
|
(94
|
)
|
|
$
|
(165,119
|
)
|
|
$
|
(3,739
|
)
|
|
Years Ended
December 31,
|
|||||||
|
2018
|
|
2017
|
|
2016
|
|||
Statutory rate
|
(21
|
)%
|
|
(34
|
)%
|
|
(34
|
)%
|
State taxes, net of federal benefit
|
(4
|
)
|
|
(5
|
)
|
|
(5
|
)
|
Nondeductible IPR&D
|
6
|
|
|
(1
|
)
|
|
3
|
|
Contingent consideration
|
1
|
|
|
(18
|
)
|
|
—
|
|
Tax credits
|
(10
|
)
|
|
(2
|
)
|
|
(3
|
)
|
Foreign income tax rate differential
|
2
|
|
|
5
|
|
|
2
|
|
Impact of 2017 Act
|
—
|
|
|
27
|
|
|
—
|
|
Other
|
—
|
|
|
5
|
|
|
(1
|
)
|
Valuation allowance
|
26
|
|
|
(14
|
)
|
|
36
|
|
Net
|
—
|
%
|
|
(37
|
)%
|
|
(2
|
)%
|
|
For Years Ended
December 31,
|
||||||
(in thousands)
|
2018
|
|
2017
|
||||
Deferred tax assets
|
|
|
|
||||
Intellectual property
|
$
|
48,339
|
|
|
$
|
44,573
|
|
Amortization/depreciation
|
3,732
|
|
|
3,082
|
|
||
Research tax credit
|
96,509
|
|
|
43,382
|
|
||
Net operating loss carry forwards
|
248,398
|
|
|
221,912
|
|
||
Deferred revenue
|
4,401
|
|
|
6,158
|
|
||
Non-cash stock issue
|
16,850
|
|
|
10,751
|
|
||
Interest carry forward limitation
|
1,032
|
|
|
—
|
|
||
Others
|
10,852
|
|
|
7,328
|
|
||
Gross deferred tax assets
|
430,113
|
|
|
337,186
|
|
||
Deferred tax liabilities
|
|
|
|
||||
Business acquisition
|
(6,465
|
)
|
|
(6,465
|
)
|
||
Royalty payable
|
(48,339
|
)
|
|
(44,573
|
)
|
||
Convertible notes
|
(16,666
|
)
|
|
(18,991
|
)
|
||
Advanced R&D payments
|
(2,103
|
)
|
|
(3,069
|
)
|
||
Total net deferred tax assets
|
356,540
|
|
|
264,088
|
|
||
Less: valuation allowance
|
(363,005
|
)
|
|
(270,553
|
)
|
||
Net deferred tax liability
|
$
|
(6,465
|
)
|
|
$
|
(6,465
|
)
|
•
|
a payment for an identifiable benefit, and
|
•
|
the identifiable benefit is separable from the existing relationship between the Company and GSK, and
|
•
|
the identifiable benefit can be obtained from a party other than GSK, and
|
•
|
the Company can reasonably estimate the fair value of the identifiable benefit,
|
(in thousands, except per share amounts)
|
Years Ended December 31,
|
||||||||||
Historical
|
2018
|
|
2017
|
|
2016
|
||||||
Numerator:
|
|
|
|
|
|
||||||
Net loss attributable to common stockholders
|
$
|
(348,995
|
)
|
|
$
|
(284,002
|
)
|
|
$
|
(200,042
|
)
|
Denominator:
|
|
|
|
|
|
||||||
Weighted average common shares outstanding — basic and diluted
|
185,790,021
|
|
|
153,355,144
|
|
|
134,401,588
|
|
|
Year ended December 31,
|
|||||||
(in thousands)
|
2018
|
|
2017
|
|
2016
|
|||
Options to purchase common stock
|
15,810
|
|
|
15,181
|
|
|
15,528
|
|
Convertible debt
|
40,850
|
|
|
40,850
|
|
|
40,850
|
|
Outstanding warrants, convertible to common stock
|
2,657
|
|
|
3,110
|
|
|
3,110
|
|
Unvested restricted stock units
|
3,712
|
|
|
2,575
|
|
|
744
|
|
Vested restricted stock units, unissued
|
91
|
|
|
50
|
|
|
—
|
|
Total number of potentially issuable shares
|
63,120
|
|
|
61,766
|
|
|
60,232
|
|
|
Quarters Ended
|
||||||||||||||
|
March 31
|
|
June 30
|
|
September 30
|
|
December 31
|
||||||||
2018
|
|
|
|
|
|
|
|
||||||||
Net loss
|
$
|
(49,916
|
)
|
|
$
|
(61,833
|
)
|
|
$
|
(159,163
|
)
|
|
$
|
(78,083
|
)
|
Basic and diluted net loss per common share (1)
|
$
|
(0.28
|
)
|
|
$
|
(0.33
|
)
|
|
$
|
(0.84
|
)
|
|
$
|
(0.43
|
)
|
2017
|
|
|
|
|
|
|
|
||||||||
Net loss
|
$
|
(54,992
|
)
|
|
$
|
(48,136
|
)
|
|
$
|
(111,666
|
)
|
|
$
|
(69,208
|
)
|
Basic and diluted net loss per common share (1)
|
(0.39
|
)
|
|
(0.34
|
)
|
|
(0.69
|
)
|
|
(0.42
|
)
|
(1)
|
Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.
|
(a)
|
1.
Consolidated Financial Statements
|
|
|
|
|
Incorporated by Reference
to SEC Filing
|
|
|
|||||
Exhibit
No.
|
|
Filed Exhibit Description
|
|
Form
|
|
Date
|
|
Exhibit No.
|
|
Filed with this
Form 10-K
|
|
2.1
|
|
|
Form 8-K
|
|
2/12/2014
|
|
2.1
|
|
|
|
|
2.2
|
|
|
Form 8-K
|
|
9/30/2015
|
|
2.2
|
|
|
|
|
+2.3
|
|
|
Form 8-K
|
|
7/6/2016
|
|
2.1
|
|
|
|
|
+2.4
|
|
|
Form 8-K
|
|
9/25/2018
|
|
2.1
|
|
|
|
|
3.1
|
|
|
Form 10-K
|
|
2/28/2012
|
|
3.1
|
|
|
|
|
3.2
|
|
|
S-1/A (333-141700)
|
|
4/27/2007
|
|
3.4
|
|
|
|
|
3.3
|
|
|
Form 8-K
|
|
6/10/2015
|
|
3.1
|
|
|
|
|
3.4
|
|
|
Form 8-K
|
|
6/8/2018
|
|
3.1
|
|
|
|
|
4.1
|
|
|
S-1 (333-141700)
|
|
3/30/2007
|
|
4.1
|
|
|
|
|
4.2
|
|
|
S-1 (333-141700)
|
|
3/30/2007
|
|
4.2
|
|
|
|
|
4.3
|
|
|
Form 8-K
|
|
10/1/2015
|
|
4.1
|
|
|
|
|
4.4
|
|
|
Form 8-K
|
|
2/22/2016
|
|
4.1
|
|
|
|
|
|
|
|
Incorporated by Reference
to SEC Filing
|
|
|
|||||
Exhibit
No.
|
|
Filed Exhibit Description
|
|
Form
|
|
Date
|
|
Exhibit No.
|
|
Filed with this
Form 10-K
|
|
4.5
|
|
|
Form 8-K
|
|
7/1/2016
|
|
4.1
|
|
|
|
|
4.6
|
|
|
Form S-3ASR
|
|
4/29/2016
|
|
4.7
|
|
|
|
|
4.7
|
|
|
Form 8-K
|
|
12/21/2016
|
|
4.1
|
|
|
|
|
*10.1
|
|
|
S-1/A (333-141700)
|
|
4/27/2007
|
|
10.1
|
|
|
|
|
+10.2
|
|
|
Form 10-K
|
|
2/6/2009
|
|
10.3
|
|
|
|
|
+10.3
|
|
|
S-1 (333-141700)
|
|
3/30/2007
|
|
10.5
|
|
|
|
|
10.4
|
|
|
S-1 (333-141700)
|
|
3/30/2007
|
|
10.17
|
|
|
|
|
*10.5
|
|
|
Form 8-K
|
|
6/18/2010
|
|
10.2
|
|
|
|
|
*10.6
|
|
|
S-1/A (333-141700)
|
|
5/17/2007
|
|
10.24
|
|
|
|
|
*10.7
|
|
|
Form 8-K
|
|
6/9/2016
|
|
10.1
|
|
|
|
|
10.8
|
|
|
Form 8-K
|
|
8/16/2011
|
|
10.1
|
|
|
|
|
|
|
|
Incorporated by Reference
to SEC Filing
|
|
|
|||||
Exhibit
No.
|
|
Filed Exhibit Description
|
|
Form
|
|
Date
|
|
Exhibit No.
|
|
Filed with this
Form 10-K
|
|
10.9
|
|
|
Form 8-K
|
|
11/20/2013
|
|
10.1
|
|
|
|
|
10.10
|
|
|
Form 8-K
|
|
12/30/2013
|
|
10.1
|
|
|
|
|
+10.11
|
|
|
Form 10-K
|
|
3/3/2014
|
|
10.46
|
|
|
|
|
*10.12
|
|
|
Form 8-K
|
|
7/2/2014
|
|
10.1
|
|
|
|
|
10.13
|
|
|
Form 8-K
|
|
10/16/2014
|
|
10.1
|
|
|
|
|
*10.14
|
|
|
Form 8-K
|
|
4/25/2014
|
|
10.1
|
|
|
|
|
*10.15
|
|
|
Form 8-K
|
|
4/25/2014
|
|
10.2
|
|
|
|
|
*10.16
|
|
|
Form 8-K
|
|
4/25/2014
|
|
10.3
|
|
|
|
|
*10.17
|
|
|
Form 10-Q
|
|
5/5/2014
|
|
10.6
|
|
|
|
|
*10.18
|
|
|
Form 10-Q
|
|
5/5/2014
|
|
10.8
|
|
|
|
|
*10.19
|
|
|
Form 8-K
|
|
6/13/2016
|
|
10.1
|
|
|
|
|
*10.20
|
|
|
Form 8-K
|
|
10/28/2016
|
|
10.1
|
|
|
|
|
*10.21
|
|
|
Form 10-K
|
|
2/29/2016
|
|
10.37
|
|
|
|
|
|
|
|
Incorporated by Reference
to SEC Filing
|
|
|
|||||
Exhibit
No.
|
|
Filed Exhibit Description
|
|
Form
|
|
Date
|
|
Exhibit No.
|
|
Filed with this
Form 10-K
|
|
*10.22
|
|
|
Form 8-K
|
|
10/16/2014
|
|
10.1
|
|
|
|
|
10.23
|
|
|
Form 8-K
|
|
4/28/2015
|
|
10.1
|
|
|
|
|
10.24
|
|
|
Form 8-K
|
|
10/1/2015
|
|
10.1
|
|
|
|
|
10.25
|
|
|
Form 8-K
|
|
9/14/2015
|
|
10.1
|
|
|
|
|
*10.26
|
|
|
Form 8-K
|
|
3/15/2016
|
|
10.1
|
|
|
|
|
10.27
|
|
|
Form 8-K
|
|
2/22/2016
|
|
10.1
|
|
|
|
|
10.28
|
|
|
Form 8-K
|
|
7/1/2016
|
|
10.2
|
|
|
|
|
*10.29
|
|
|
Form 8-K
|
|
7/29/2016
|
|
10.1
|
|
|
|
|
|
|
|
Incorporated by Reference
to SEC Filing
|
|
|
|||||
Exhibit
No.
|
|
Filed Exhibit Description
|
|
Form
|
|
Date
|
|
Exhibit No.
|
|
Filed with this
Form 10-K
|
|
*10.30
|
|
|
Form 8-K
|
|
8/23/2016
|
|
10.1
|
|
|
|
|
10.31
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.1
|
|
|
|
|
10.32
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.2
|
|
|
|
|
10.33
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.3
|
|
|
|
|
10.34
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.4
|
|
|
|
|
10.35
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.5
|
|
|
|
|
10.36
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.6
|
|
|
|
|
10.37
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.7
|
|
|
|
|
10.38
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.8
|
|
|
|
|
10.39
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.9
|
|
|
|
|
|
|
|
Incorporated by Reference
to SEC Filing
|
|
|
|||||
Exhibit
No.
|
|
Filed Exhibit Description
|
|
Form
|
|
Date
|
|
Exhibit No.
|
|
Filed with this
Form 10-K
|
|
10.40
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.10
|
|
|
|
|
10.41
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.11
|
|
|
|
|
10.42
|
|
|
Form 8-K
|
|
12/21/2016
|
|
10.12
|
|
|
|
|
*10.43
|
|
|
Form 8-K
|
|
12/30/2016
|
|
10.1
|
|
|
|
|
10.44
|
|
|
Form 8-K
|
|
9/25/18
|
|
10.1
|
|
|
|
|
10.45
|
|
|
Form 8-K
|
|
1/24/19
|
|
10.1
|
|
|
|
|
10.46
|
|
|
Form 8-K
|
|
2/8/19
|
|
10.1
|
|
|
|
|
10.47
|
|
|
Form 8-K
|
|
12/26/18
|
|
10.1
|
|
|
|
|
++10.48
|
|
|
|
|
|
|
|
|
X
|
||
10.49
|
|
|
|
|
|
|
|
|
X
|
||
21
|
|
|
|
|
|
|
|
|
|
X
|
|
23.1
|
|
|
|
|
|
|
|
|
|
X
|
|
31.1
|
|
|
|
|
|
|
|
|
|
X
|
|
31.2
|
|
|
|
|
|
|
|
|
|
X
|
|
32.1
|
|
|
|
|
|
|
|
|
|
X
|
|
32.2
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
Incorporated by Reference
to SEC Filing
|
|
|
||||
Exhibit
No.
|
|
Filed Exhibit Description
|
|
Form
|
|
Date
|
|
Exhibit No.
|
|
Filed with this
Form 10-K
|
101
|
|
The following financial information from this Annual Report on Form 10-K for the year ended December 31, 2018, formatted in XBRL (Extensible Business Reporting Language) and filed electronically herewith: (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Operations; (iii) the Consolidated Statements of Comprehensive Loss; (iv) the Consolidated Statements of Cash Flows; (v) and the Notes to the Consolidated Financial Statements.
|
|
|
|
|
|
|
|
X
|
+
|
Confidential treatment has been granted as to certain portions of the document, which portions have been omitted and filed separately with the Securities and Exchange Commission.
|
++
|
Subject to confidential treatment request.
|
*
|
Indicates management contract or compensatory plan.
|
AMICUS THERAPEUTICS, INC.
(Registrant)
|
|
By:
|
/s/ John F. Crowley
|
|
John F. Crowley
Chief Executive Officer
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ John F. Crowley
|
|
Chairman and Chief Executive Officer
(Principal Executive Officer)
|
|
February 28, 2019
|
(John F. Crowley)
|
|
|
|
|
|
|
|
|
|
/s/ Daphne Quimi
|
|
Chief Financial Officer
(Principal Financial Officer) |
|
February 28, 2019
|
(Daphne Quimi)
|
|
|
|
|
|
|
|
|
|
/s/ Samantha Prout
|
|
Global Controller
(Principal Accounting Officer) |
|
February 28, 2019
|
(Samantha Prout)
|
|
|
|
|
|
|
|
|
|
/s/ Robert Essner
|
|
Director
|
|
February 28, 2019
|
(Robert Essner)
|
|
|
|
|
|
|
|
|
|
/s/ Ted W. Love, M.D.
|
|
Director
|
|
February 28, 2019
|
(Ted W. Love, M.D.)
|
|
|
|
|
|
|
|
|
|
/s/ Margaret G. McGlynn, R.Ph.
|
|
Director
|
|
February 28, 2019
|
(Margaret G. McGlynn, R.Ph.)
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Michael G. Raab
|
|
Director
|
|
February 28, 2019
|
(Michael G. Raab)
|
|
|
||
|
|
|
|
|
/s/ Glenn Sblendorio
|
|
Director
|
|
February 28, 2019
|
(Glenn Sblendorio)
|
|
|
||
|
|
|
|
|
/s/ Craig Wheeler
|
|
Director
|
|
February 28, 2019
|
(Craig Wheeler)
|
|
|
||
|
|
|
|
|
/s/ Lynn Bleil
|
|
Director
|
|
February 28, 2019
|
(Lynn Bleil)
|
|
|
1.1
|
“
AAV
” means adeno-associated virus.
|
1.2
|
“
Achievement Date
” means with respect to a Diligence Event, the corresponding date such Diligence Event is to be achieved as provided in Sections 5.7 and 5.8 below.
|
1.3
|
“
Affiliate
” means with respect to a Person, any corporation or other business entity that controls, is controlled by or is under common control with such Person, but only for so long as such control exists. For the purposes of this Section 1.3, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means the affirmative power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.
|
1.4
|
“
BLA
” means (a) a Biologics License Application as defined in the FD&C Act and the regulations promulgated thereunder, (b) a Marketing Authorization Application (“
MAA
”) in the European Union, or (b) any equivalent or comparable application, registration or certification in any other country or region.
|
1.5
|
“
Calendar Quarter
” mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31 of each Calendar Year.
|
1.6
|
“
Calendar Year
” means each successive period of twelve (12) months commencing on January 1 and ending on December 31.
|
1.7
|
“cGLP”
means the current good laboratory practice regulations promulgated by the FDA, published at 21 U.S C.F.R. § 58, and equivalent non-United States regulations and standards in the Territory, as applicable, as such current laboratory practices, regulations and standards may be amended from time to time.
|
1.8
|
“cGMP”
means those current practices, as amended from time to time, related to the manufacture of pharmaceutical products and any precursors thereto promulgated in guidelines and regulations of standard compilations including the GMP Rules of the World Health Organization, the United States Code of Federal Regulations, the Guide to Inspection of Bulk Pharmaceutical Chemicals (established by the United States Department of Health and Human Services), the Pharmaceutical Inspection Convention, and the European Community Guide to Good Manufacturing Practice in the production of pharmaceutical products, and equivalent guidelines, regulations and standards in the Territory, as such guidelines, regulations and standards may be amended from time to time.
|
1.9
|
“
Challenge
” means Licensee or a Sublicensee will be deemed to have made a “Challenge” of the Penn Patent Rights if Licensee or a Sublicensee: (a) institutes or voluntarily joins as a party to, or causes its counsel to institute on Licensee’s or such Sublicensee’s behalf, any interference, opposition, re-examination, post-grant review or similar proceeding with respect to any Penn Patent Right with the U.S. Patent and Trademark Office or any foreign patent office; or (b) files or voluntarily joins as a party to any legal proceeding, or causes its counsel to institute or voluntarily join as a party to any legal proceeding on Licensee's or such Sublicensee's behalf, with a court or other Governmental Body (including, without limitation, the U.S. Patent and Trademark Office or any foreign patent office) having authority to determine the validity, enforceability or scope of the Penn Patent Rights, in which one or more claims in such legal proceeding challenges the validity or enforceability of any Penn Patent Right.
|
1.10
|
“
Change of Control
” means the occurrence of any of the following events: (a) any party becomes the owner, directly or indirectly, of more than fifty percent (50%) of the total voting power (on an as converted basis) of the equity units or other interests of Licensee then outstanding that are normally entitled to vote in the election of directors of Licensee other than in connection with a financing or series of financing transactions; (b) the merger, consolidation or amalgamation of Licensee with or into any other party, other than any transaction in which the holders of the outstanding voting securities of Licensee immediately prior to the transaction own, directly or indirectly, not less than fifty percent (50%) of the total voting power (on an as converted basis) of the voting securities of the party surviving such merger, consolidation or amalgamation; or (c) the sale of all or substantially all of the assets of Licensee.
|
1.11
|
“
Clinical Study
” means (a) a Phase 1 Study, Phase 1/2 Study, Phase 2 Study, or Phase 3 Study, or (b) such other study in humans that is conducted in accordance with good clinical practices and is designed to generate data in support or maintenance of an application for Regulatory Approval.
|
1.12
|
“
Commercially Reasonable Efforts
” means [***].
|
1.13
|
“
Compulsory License
” means a compulsory license under Penn Patent Rights obtained by a Third Party through the order, decree, or grant of a competent Governmental Body or court, authorizing such Third Party to develop, make, have made, use, sell, offer to sell or import a Licensed Product in any country.
|
1.14
|
“
Confidential Information
” of a Party, means (i) confidential or proprietary information or materials relating to the business, operations, technology or products of a Party or any of its Affiliates, including any know-how, that such Party discloses to the other Party under this Agreement, or otherwise makes available to the other Party under this Agreement, and (ii) the terms of this Agreement; provided that Confidential Information shall not include information that:
|
(a)
|
is or becomes generally available to the public other than as a result of disclosure by the recipient in breach of this Agreement;
|
(b)
|
is already known by or in the possession of the recipient at the time of disclosure by the disclosing Party;
|
(c)
|
is independently developed by recipient without use of or reference to the disclosing Party’s Confidential Information; or
|
(d)
|
is obtained by recipient from a Third Party that has not breached any obligations of confidentiality to the disclosing party.
|
1.15
|
“
Controlled
” means, with respect to intellectual property rights, that a Party or one of its Affiliates owns or has a license or sublicense to such intellectual property rights and has the ability to provide to, grant a license or sublicense to, or assign its right, title and interest in and to, such intellectual property rights as provided for in the Agreement without violating the terms of any other agreement or other arrangement with any Third Party.
|
1.16
|
“
Designated Product
” means a Licensed Product arising from the Research Program [***].
|
1.17
|
“
Development Transition Point
” or “
DTP
” means on a Licensed Product-by-Licensed Product basis the date on which the IND enabling studies for a Pre-Designation Product under the Research Program have been successfully completed and immediately prior to filing of the IND, unless otherwise agreed by the Parties.
|
1.18
|
“Diligence Event”
means each of the events that Licensee is expected to accomplish in the development of a Licensed Product in each Indication set forth in Sections 5.7 and 5.8.
|
1.19
|
“
EMA
” means the European Medicines Agency and any successor entity thereto.
|
1.20
|
“
FDA
” means the United States Food and Drug Administration and any successor entity thereto.
|
1.21
|
“
FD&C Act
” means the United States Federal Food, Drug and Cosmetic Act, as amended.
|
1.22
|
“
Field of Use
” means all research, prophylactic, diagnostic and therapeutic uses in or for humans. For clarity, except for any uses in non-humans intended to support development for prophylactic, diagnostic and/or therapeutic use in humans, any and all uses in non-humans, including any and all veterinary uses in companion animals and livestock species, is excluded from the Field of Use.
|
1.23
|
“
FIH
” means, on a Licensed Product-by-Licensed Product basis, the first dosing of the first patient in a Clinical Study.
|
1.24
|
“
First Commercial Sale
” means, on a country-by-country basis, the first commercial transfer or disposition for monetary value of Licensed Product in such country for use or consumption by a Third Party end user by Licensee, or any of its Affiliates or Sublicensees, in each case, after all Regulatory Approvals have been obtained for such country and where such disposition or transfer results in a recordable Net Sale in accordance with Licensee’s, or its Affiliate’s or Sublicensee’s, applicable accounting practices (consistently applied). Sales prior to receipt of Regulatory Approval of a Licensed Product such as so-called “treatment IND sales,” “named patient sales,” “compassionate use sales” or expanded access programs, shall not be considered a First Commercial Sale.
|
1.25
|
“
Force Majeure Event
” means any circumstance beyond the affected Party’s reasonable control to forsee, including, without limitation, labor disturbances or labor disputes of any kind, unforeseeable acts, omissions or delays in acting by any Governmental Body required for full performance (except to the extent such delay results from a breach by the affected Party of a term of this Agreement), civil disorders or commotions, strikes, acts of war, terrorism, acts of God, energy or other conservation measures imposed by law or regulation, explosions, failure of utilities, mechanical breakdowns, material shortages, or disease.
|
1.26
|
“
FPFD
” means, on a Licensed Product-by Licensed Product basis with respect to each Clinical Study, the first dosing of the first patient in such Clinical Study.
|
1.27
|
“
GAAP
” means United States generally accepted accounting principles applied on a consistent basis.
|
1.28
|
“
Generic Product
” means, with respect to a particular Licensed Product in a country, a generic or biosimilar pharmaceutical product, that is not licensed or owned by Licensee, any of its Affiliates or Sublicensees, that is approved for use in such country by a Regulatory Authority by referencing the prior approval, in whole or part, or safety and efficacy data submitted in support of the prior approval, of such Licensed Product.
|
1.29
|
“
Governmental Body
” means any: (a) nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, provincial, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d) multi-national or supranational organization or body; or (e) individual, entity, or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.
|
1.30
|
“
IND
” means an Investigational New Drug Application as defined in the FD&C Act and the regulations promulgated thereunder, or (b) an equivalent application to an equivalent Regulatory Authority in any other regulatory jurisdiction, including a Clinical Trial Authorization (“
CTA
”) to the European Medicines Agency, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction.
|
1.31
|
“
Indication
” means each of a) CDKL5 deficiency through AAV delivery of nucleic acid polymers [***], b) Pompe Disease through AAV delivery of nucleic acid polymers, c) Fabry Disease through AAV delivery of nucleic acid polymers and d) AAV delivery of nucleic acid polymers for [***].
|
1.32
|
“
Joint Patent Rights
” means (a) any Patent Rights covering an invention conceived and reduced to practice jointly by the Wilson Lab and Licensee in the conduct of a Research Program, (b) any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues of any of the Patent Rights in (a), including divisions, but excluding continuations-in-part except to the extent of claims solely supported in the specification and entitled to the priority date of the parent application for any of the foregoing, and (c) any corresponding Patent Rights to the foregoing outside of the United States.
|
1.33
|
“
Know-How
” means intellectual property, data, results, pre-clinical and clinical protocols and study data, chemical structures, chemical sequences, information, inventions, formulas, techniques, methods, processes, procedures and developments. “Know-How” does not include any of the foregoing claimed in a Penn Patent Right or Patent Right Controlled by Licensee.
|
1.34
|
“
Law
” or “
Laws
” means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the binding effect of law of any Governmental Body.
|
1.35
|
“
Licensed Know-How
” means all Know-How that is Controlled by Penn as of the Effective Date or during the Research Term and (a) developed by the Wilson Lab as of the Effective Date of the Agreement, (b) developed in the Wilson Lab under the Next Generation Program or (c) developed in the Wilson Lab under a Research Program, and in each case (a), (b) and (c) is necessary or reasonably useful to develop, make, use, sell, offer for sale or import a Licensed Product for an Indication in the Field of Use.
|
1.36
|
“
Licensed
Product
” means any (a) article, composition, apparatus, substance, chemical or any other material covered by a Program Valid Claim or whose manufacture, import, use, offer for sale or sale would, absent the License, constitute an infringement, inducement of infringement or contributory infringement of any Program Valid Claim or would infringe a Program Valid Claim once issued; (b) article, composition, apparatus, chemical, substance or any other material made, used or sold by or utilizing or practicing a Method, (c) article, composition, apparatus, substance, chemical or any other material that incorporates, uses or is made through the use of any Licensed Know-How and is an AAV gene therapy for an Indication or (d) any AAV gene therapy for an Indication conceived during or tested in the Research Program. Notwithstanding the foregoing, “Licensed Product” shall not include a product, to the extent it would have solely been a Licensed Product pursuant to subsection (c) above, that is, or was prior to the Effective Date, (i) acquired or licensed by Licensee or any of its Affiliates (including pursuant to a Change of Control) or (ii) controlled by a Third Party acquirer of Licensee or any of its Affiliates (whether by merger or acquisition of all or substantially all of the stock or assets of Licensee or its Affiliate or a similar transaction) and, in each case ((i) and (ii)), that has been independently developed by a Third Party and for which [***] prior to the closing of such acquisition or license by Licensee or any of its Affiliates (with respect to clause (i) above) or such merger, acquisition or similar transaction (with respect to clause (ii) above).
|
1.37
|
“
Major Markets
” means the [***].
|
1.38
|
“
Manufacturing Patent Rights
” means, [***] any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues thereof, including divisions, but excluding continuations-in-part except to the extent of claims solely supported in the specification and entitled to the priority date of the parent application, and (c) any corresponding foreign Patent Rights to the foregoing.
|
1.39
|
“
Method
” means process or method covered by a Program Valid Claim or whose use or practice would, absent the License, constitute an infringement, inducement of infringement or contributory infringement of any Program Valid Claim, or would infringe a Program Valid Claim once issued.
|
1.40
|
“
Net Sales
” means the gross amounts billed, invoiced or received by Licensee or any of its Affiliates or Sublicensees for Sales of Licensed Product (including any cash amounts plus the fair market value of any other forms of consideration), less the following deductions to the extent reasonable customary, and actually deducted:
|
1.40.1
|
[***];
|
1.40.2
|
[***];
|
1.40.3
|
[***];
|
1.40.4
|
[***];
|
1.40.5
|
[***].
|
1.41
|
“
Next Generation Capsid
” means a specific AAV identified by sequence that is discovered, developed or engineered in the Next Generation Program.
|
1.42
|
“
Next Generation Capsid Data Package
” means a written data package prepared by the Wilson Lab with respect to a Next Generation Capsid containing: [***].
|
1.43
|
“
Next Generation Program
” means [***].
|
1.44
|
“
Next Generation Program Period
” means [***] or (b) if the funding for the Next Generation Program is extended beyond [***], the earlier of (i) the expiration or termination of the Research Term or (ii) the end of funding for the Next Generation Program. Penn shall promptly notify Licensee if funding for the Next Generation Program is so extended.
|
1.45
|
“
Patent Rights
” means (a) patents and patent applications, together with any unlisted patents and patent applications claiming priority thereto, and any continuations, continuations-in-part (to the extent related directly to the subject matter of the parent application or containing new information developed pursuant to the Research Program), reissues, reexamination certificates, substitutions, divisionals, supplementary protection certificates, renewals, registrations, extensions including all confirmations, revalidations, patents of addition, PCTs, and pediatric exclusivity periods and all foreign counterparts thereof, and any patents issued or issuing with respect to any of the foregoing and (b) all official correspondence relating to the foregoing.
|
1.46
|
“
Penn Patent Rights
” means Penn Patent Rights A (including Penn’s interest in the Joint Patent Rights), Penn Patent Rights B, Penn Patent Rights C, and Manufacturing Patent Rights, collectively.
|
1.47
|
“
Penn Patent Rights A
” means [***] any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues of any of the Patent Rights in (a) or (b), including divisions, but excluding continuations-in-part except to the extent of claims solely supported in the specification and entitled to the priority date of the parent application for any of the foregoing, and (d) any corresponding foreign Patent Rights to the foregoing.
|
1.48
|
“
Penn Patent Rights B
” means [***] (b) any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues thereof, including divisions, but excluding continuations-in-part except to the extent of claims entirely solely supported in the specification and entitled to the priority date of the parent application for any of the foregoing, and (c) any corresponding foreign Patent Rights to the foregoing.
|
1.49
|
“
Penn Patent Rights C
” means [***] any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues thereof, including divisions, but excluding continuations-in-part except to the extent of claims solely supported in the specification and entitled to the priority date of the parent application, and (c) any corresponding foreign Patent Rights to the foregoing.
|
1.50
|
“
Person
” means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or agency or political subdivision thereof.
|
1.51
|
“
Phase 1 Study
” means a clinical study of a drug candidate in patients with the primary objective of characterizing its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies as described in 21 C.F.R. 312.21(a), or a comparable clinical study prescribed by the relevant regulatory authority in a country other than the United States. The drug candidate can be administered to patients as a single agent or in combination with other investigational or marketed agents.
|
1.52
|
“
Phase 1/2 Study
” means a clinical study of a drug candidate in diseased patients that satisfies the requirements of a Phase 1 Study and a Phase 2 Study.
|
1.53
|
“
Phase 2 Study
” means a clinical study of a drug candidate in patients with the primary objective of characterizing its activity in a specific disease state as well as generating more detailed safety, tolerability, and pharmacokinetics information as described in 21 C.F.R. 312.21(b), or a comparable clinical study prescribed by the relevant regulatory authority in a country other than the United States including a human clinical trial that is also designed to satisfy the requirements of 21 C.F.R. 312.21(a) or corresponding foreign regulations and is subsequently optimized or expanded to satisfy the requirements of 21 C.F.R. 312.21(b) (or corresponding foreign regulations) or otherwise to enable a Phase 3 Clinical Study (e.g., a phase 1/2 trial). The relevant drug candidate may be administered to patients as a single agent or in combination with other investigational or marketed agents.
|
1.54
|
“
Phase 3 Study
” means a clinical study of a drug candidate in patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety in order to obtain Regulatory Approval in any country, as further described in 21 C.F.R. 312.21(c) with respect to the United States, or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. The relevant drug candidate may be administered to patients as a single agent or in combination with other investigational or marketed agents.
|
1.55
|
“
Pivotal Study
” means Phase 3 Study or other clinical study of a drug candidate in human patients with the disease being studied, in each case, the principal purpose of which is to achieve a determination of efficacy and safety and is designed and intended to provide the basis for obtaining Regulatory Approval to market the applicable product for patients with the indication being studied or where a Clinical Study subsequently is deemed to achieve efficacy and safety for the applicable product and indication for the purpose of obtaining Regulatory Approval.
|
1.56
|
“
Potential Indications
” means [***] in each case (a) through AAV delivery of nucleic acid polymers, [***].
|
1.57
|
“
Pre-Designation Product
” means an AAV gene therapy product for an Indication arising from the Research Program for which the time period within which Licensee must provide notice to Penn under Section 2.6 has not yet expired.
|
1.58
|
“
Program Valid Claim
” means a claim of (a) an issued and unexpired patent in Penn Patent Rights A which claim has not been revoked or held unenforceable or invalid by a decision of a court of governmental agency of competent jurisdiction from which no further appeal can be taken or has been taken within the time allowed for appeal, and has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer; or (b) a pending patent application that is included in Penn Patent Rights A which was filed and is being prosecuted, and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application and has not been pending for more than [***].
|
1.59
|
“
Regulatory Approval
” means, with respect to a product in any regulatory jurisdiction, approval from the applicable Regulatory Authority sufficient for the manufacture, distribution, use, marketing and sale of such pharmaceutical product in such jurisdiction in accordance with Laws (including, where applicable, any pricing or reimbursement approvals). “Regulatory Approval” does not include authorization by a Regulatory Authority to conduct named patient, compassionate use or other similar activities.
|
1.60
|
“
Regulatory Authority
” means any governmental authority, including the FDA, EMA or MHLW, or any successor agency thereto, that has responsibility for granting any licenses or approvals or granting pricing or reimbursement approvals necessary for the marketing and sale of a pharmaceutical product in any country.
|
1.61
|
“
Regulatory Exclusivity
” means with respect to any country or jurisdiction, any exclusive marketing rights or data exclusivity protection conferred by an applicable Regulatory Authority or other Regulatory Authority in such country or jurisdiction with respect to a compound or bio-pharmaceutical product, including any regulatory data protection exclusivity (including any orphan drug designation or pediatric exclusivity).
|
1.62
|
“
Research Plan
” means the research plan setting forth the Parties’ roles and responsibilities for the Research Program as set forth in
Exhibit B
hereto, respectively, and as may be amended from time to time with written approval of the JSC.
|
1.63
|
“
Research Program
” means the research, pre-clinical development and development program of Licensed Products in the Field for the Indications funded by Licensee and to be conducted by the Wilson Lab and Licensee hereunder pursuant to the Research Plan.
|
1.64
|
“
Research Results
” means all any and all ideas, information, inventions, developments, animate and inanimate materials, including live animals, discoveries, software, know-how, methods, techniques, formulae, data, software, processes, methodologies, techniques, biological materials, software and works of authorship, whether patentable or copyrightable, that are first conceived, discovered, developed or reduced to practice, or generated in the performance of the Research Program by the Wilson Lab, including any unpatentable inventions discovered, developed or conceived in the conduct of the Research Program. Research Results expressly excludes any such items covered by Penn Patent Rights and Joint Patent Rights.
|
1.65
|
“
Sale
” means any transaction for which consideration is received or expected by Licensee, its Affiliates or Sublicensees for sale, use, lease, transfer or other disposition of a Licensed Product to or for the benefit of a Third Party. For clarity, sale, use, lease, transfer or other disposition of a Licensed Product by Licensee or any of its Affiliates or Sublicensees to another of these entities for resale by such entity to a Third Party shall not be deemed a Sale.
|
1.66
|
“
Service Center Cores
” means the following core laboratories at Penn that report directly to Dr. James Wilson, all science cores, including the Animal Models Core, the Vector Core, the Immunology Core, the Cell Morphology Core, the Biostatistics Core and the Integrated Technology Core.
|
1.67
|
“
Sublicensee
” means a Third Party to which a Sublicense is granted pursuant to the terms of Section 3.6.
|
1.68
|
“
Sublicense Documents
” means any and all agreements, amendments or written understandings entered into with a Sublicensee (including any of its Affiliates) pertaining to a Sublicense, Penn Patent Rights or Licensed Product. For clarity, a development agreement or distribution agreement for a Licensed Product is a Sublicense Document.
|
1.69
|
“
Sublicense Income
” means payments received by Licensee or its Affiliates from a Sublicensee in consideration for a Sublicense or other agreement providing the right to negotiate or obtain a Sublicense. Sublicense Income includes payments received from a Sublicensee in the form of license issue fees, milestone payments and the like, but specifically excludes [***
]
.
|
1.70
|
“
Tax
” means all taxes, duties, fees, premiums, assessments, imposts, levies, rates, withholdings, dues, government contributions and other charges of any kind whatsoever, whether direct or indirect, together with all interest, penalties, fines, additions to tax or other additional amounts, imposed by any Governmental Body.
|
1.71
|
“
Third Party
” means any Person other than Penn, Licensee or any of their respective Affiliates.
|
1.72
|
“
United States
” or “
US
” means the United States of America, its territories and possessions.
|
1.73
|
“
USD
” or “
$
” means the lawful currency of the United States of America.
|
1.74
|
“
Valid Claim
” means a claim of (a) an issued and unexpired patent in Penn Patent Rights which claim has not been revoked or held unenforceable or invalid by a decision of a court of governmental agency of competent jurisdiction from which no further appeal can be taken or has been taken within the time allowed for appeal, and has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer; or (b) a pending patent application that is included in Penn Patent Rights which was filed and is being prosecuted, and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application and has not been pending for more than [***].
|
1.75
|
“
Wilson Lab
” means Dr. James M. Wilson and all individuals who are under the direct supervision or control of Dr. James M. Wilson or his successor as Director of the Wilson Gene Therapy Program at Penn, provided that the Service Center Cores are not included in the Wilson Lab, including any personnel of the Service Center Cores.
|
1.76
|
Other Terms
. The definition of each of the following terms is set forth in the section of the Agreement indicated below:
|
Defined Term
|
Section
|
Advance Payment
|
6.2.3
|
Agreement
|
Introductory Clause
|
Amicus Technology
|
3.3
|
Bankruptcy Action
|
10.3.4
|
Carve-Out Patent Rights
|
6.1.2
|
Budget
|
2.3.1
|
Capsid Notice
|
2.5.2
|
Commercial Milestone
|
4.2.2(a)
|
Commercial Milestone Payment
|
4.2.2(a)
|
CTA
|
1.30
|
Development Milestone
|
4.2.1(a)
|
Development Milestone Payment
|
4.2.1(a)
|
Disclosing Party
|
7.1
|
Effective Date
|
Introductory Clause
|
Election Notice
|
2.7.2
|
Exclusivity Period
|
2.7
|
Extension Event
|
5.8
|
Failed Indication
|
2.9
|
Failed Indication Notice
|
2.9
|
Financial Report
|
4.6
|
Historic Patent Costs
|
6.2.1
|
Infringement Notice
|
6.3.1
|
Joint Intellectual Property Committee (“JIPC”)
|
2.11.2(a)
|
Joint Steering Committee (“JSC”)
|
2.11.1
|
Liabilities
|
9.1.1
|
License
|
3.1
|
License Maintenance Fee
|
4.1.3
|
Licensee
|
Introductory Clause
|
Licensee Data
|
2.10
|
Limited Exclusivity Covenant
|
2.7
|
MAA
|
1.4
|
New Collaboration Agreement
|
2.7.3
|
New Indication
|
1.31
|
New Indication Option
|
2.4
|
New Indication Option Fee
|
4.1.4
|
New Program Plan/Budget
|
2.4
|
Offer Notice
|
2.7.1
|
Ongoing Patent Costs
|
6.2.2
|
Party or Parties
|
Introductory Clause
|
Patent Costs
|
6.2.1
|
Patent Counsel
|
6.1.1
|
Penn
|
Introductory Clause
|
Penn Data
|
2.10
|
Penn Indemnitees
|
9.1.1
|
Penn Sublicense Income
|
4.4.1
|
Product-Specific Patent Rights
|
6.1.1
|
Progress Report
|
5.9.1
|
Prosecution Request
|
6.1.2
|
Receiving Party
|
7.1
|
Research Support Amount
|
2.2.1
|
Research Term
|
2.2.1
|
Reserved Capsid
|
2.5.2
|
Royalty
|
4.3.1
|
Royalty Period
|
4.3.2
|
Sale Transaction
|
1.69
|
Service Provider Sublicensee
|
3.6.4
|
Sublicense
|
3.6.1
|
Substitute Capsid
|
2.5.2
|
Term
|
10.1
|
Third Party IP
|
4.3.3(b)(i)
|
Wilson Lab
|
1.75
|
2.1
|
Overall Project
. The Parties desire to collaborate with respect to the pre-clinical development of an AAV gene therapy product, as set forth in more detail in this Article 2, for each Indication within the Field of Use, with the goal of designating one Licensed Product for clinical development and commercialization for each Indication in the Field of Use. Penn will be responsible for preclinical development activities, including all IND-enabling non-clinical studies and research grade manufacturing, and all activities allocated to Penn as set forth in the Research Plan. Licensee will be responsible for those activities allocated to Licensee in the Research Plan and for regulatory strategy and operations, clinical development, cGMP manufacture, and commercialization of all Licensed Product(s).
|
2.2
|
Research
.
|
2.2.1
|
During the period of [***] following the Effective Date (“
Research Term
”), subject to the terms and conditions of this Agreement, Licensee shall provide $[***] based on the Research Plan for research and development funding (“
Research Support Amount
”) to Penn to fund the Research Program. Such Research Support Amount shall be inclusive of Penn’s standard indirect charges. Licensee shall remit such funds in each year of the Research Term in accordance with Section 2.3 below and such funds will be allocated and utilized solely to support the Research Program as set forth in the Research Plan.
|
2.2.2
|
Penn will conduct the Research Program in accordance with the Research Plan and the other terms and conditions of this Agreement. Without limiting the foregoing, within each Indication, Penn will be responsible for the completion of the Research Plan for the research and development work up to completion of IND enabling studies, including animal model development, and IND supporting preclinical work (toxicology and pharmacokinetics) and manufacturing to support preclinical development of a Licensed Product for each Indication under the Research Program through DTP.
|
2.2.3
|
The JSC shall review the Research Plan at least once per Calendar Year. The JSC may amend the Research Plan at any time, including amendments to include further activities, including corresponding revisions to the budget.
|
2.2.4
|
Penn shall maintain records of the activities conducted under and the results of the Research Program (including the Research Results) in sufficient detail and in good scientific manner appropriate for patent purposes to properly reflect all work done and results achieved. Penn will provide task-based, scientific reports of the progress and results of the Research Program on the schedule specified in the Research Plan or on another schedule to be agreed in writing by the Parties. Penn shall maintain reasonable and accurate records of the use of the funds provided by Licensee under this Agreement and shall make such records available to Licensee (or its designee) upon reasonable notice during Penn’s normal business hours, but not more frequently once each Calendar Year. All Research Results shall be solely and exclusively owned by Penn. For the avoidance of doubt, Research Results will constitute Licensed Know-How and will be included within the scope of the Licenses granted by Penn to Licensee under this Agreement.
|
2.2.5
|
Each Party will have the right to engage Third Party subcontractors to perform certain of its obligations under this Agreement. Any subcontractor to be engaged by a Party to perform a Party’s obligations set forth in the Agreement will meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity and will enter into an appropriate agreement with such Party consistent with such Party’s standard practices which agreement shall be as least as protective as the nondisclosure and nonuse of confidential information obligations set forth herein and requiring the assignment or license of Know-How and other intellectual property generated in the course of the subcontracted work (including, with respect to any such Know-How and other intellectual property licensed to Penn, the right to grant and authorize Sublicenses under such Know-How and other intellectual property as contemplated herein in the same manner and of the same scope as required for intellectual property generated solely by the Wilson Lab). Any Party engaging a subcontractor hereunder will remain responsible and obligated for the acts and omissions of such subcontractor and will not grant rights to such subcontractor that would interfere with, limit or diminish the rights of the other Party under this Agreement.
|
2.3
|
Funding of the Research Program
.
|
2.3.1
|
The initial budget for the Research Program, broken down by Calendar Year, is set forth in
Exhibit C
(the “
Budget
”, including as subsequently amended, pursuant to this Section 2.3.1). On or before November 1 of each year, the Parties, through the JSC, will agree on an updated budget for the remainder of the Research Program, also broken down by Calendar Year. Subject to the terms and conditions of this Agreement, Licensee shall pay Penn the Research Support Amount in advance on a Calendar Quarter basis (in accordance with the payment schedule in the Budget to cover the cost of the performance of the Research Plan by Penn (including reasonable and documented direct external expenses incurred by Licensee in accordance with the Research Plan and as agreed to by the Parties through the JSC).
|
2.3.2
|
If at any time Penn determines that it will require additional funds for the Research Program, it will promptly notify Licensee through the JSC and provide a good faith estimate and itemized budget of the additional amount. Notwithstanding the foregoing, changes to the scope of or budget for the Research Plan in a Calendar Year will require approval of the JSC if the budget impact for the applicable Calendar Year (in the aggregate) is greater than the higher of [***].
|
2.3.3
|
Title to any equipment, laboratory animals, or any other tangible materials made or acquired with funds provided under this Agreement will vest in Penn, and such equipment, animals, or tangible materials will remain the property of Penn following termination or expiration of this Agreement (but subject to any license grants to Licensee hereunder).
|
2.4
|
New Indication Option.
If Licensee has interest to include one additional indication from the Potential Indications in the Research Program, Licensee shall formally notify Penn in writing within [***] after the Effective Date of such interest by indicating which indication in the Potential Indications it wishes to fund preclinical work at Penn for. Penn will then develop and propose within thirty (30) days of such written request a work plan and budget for the preclinical development activities and costs through completion of IND enabling studies to be conducted at Penn for a Licensed Product for such indication subject to the reasonable review and approval by Licensee (“
New Program Plan/Budget
”). Within thirty (30) days of Licensee’s receipt of the New Program Plan/Budget, Licensee will decide whether to exercise its option to such indication (the “
New Indication Option
”). If Licensee exercises its New Indication Option by written notice to Penn, then a) the research program with respect to such indication will become part of the Research Program, b) the Research Support Amount will be increased by the amount of the agreed budget within the New Program Plan/Budget, c) Licensee will pay the New Indication Option Fee and d) the definition of “Indication” will include such indication. For the avoidance of doubt, if Licensee does not exercise its option for a Potential Indication that is the subject of a New Program Plan/Budget, then Licensee’s New Program Option will continue for the remainder of such [***] period remaining after Effective Date or until Licensee exercises the New Program Option, whichever is earlier. If Licensee fails to exercise such New Indication Option in the time periods set forth above and provide Penn written notice of such exercise, such New Indication Option shall terminate and Penn shall be free to license any of the Potential Indications to a Third Party. In the event that none of the Potential Indications is available for inclusion in the Research Program as contemplated in this Section 2.4, the Parties will work together in good faith to identify a substitute indication which, once agreed upon, would become a Potential Indication and would be subject to the New Indication Option.
|
2.5
|
Next Generation Option
|
2.5.1
|
Generally
. It is anticipated that Licensed Product development under the Research Program for certain Indications may either [***].
|
2.5.2
|
Next Generation Capsid Data Packages
. During the term of the Next Generation Program until a Designated Product for each Indication has been determined, the Wilson Lab will notify Licensee [***] of any available
Next Generation Capsids for a Licensed Product for each Indication in the Field of Use. For each such Next Generation Capsid, the Wilson Lab will at the time of such notification provide Licensee a Next Generation Capsid Data Package and thereafter upon Licensee’s written request, provide any additional information regarding such Next Generation Capsid not previously provided. If Licensee expresses interest in any Next Generation Capsid for a Licensed Product for a specific Indication and provides Penn with written notice thereof after Licensee’s receipt of the relevant Next Generation Capsid Data Package during the Research Term (a “
Capsid Notice
”), Penn will reserve such Next Generation Capsid for the Licensed Product for such Indication until such time as Licensee determines the Designated Product for such Indication (“
Reserved Capsid
”). License may only reserve one Next Generation Capsid per Indication but may substitute another Next Generation Capsid for an Indication (“
Substitute Capsid
”) by providing Penn written notice of such substitution during the Research Term and prior to Designated Product selection for such Indication. Upon Penn’s timely receipt of such notice, the Substitute Capsid will become the Reserved Capsid for such Indication. Following Penn’s receipt of a Capsid Notice, Penn will provide Licensee with a list of Penn Patent Rights B, Penn Patent Rights C and Manufacturing Patent Rights related to such Reserved Capsid. Licensee shall be responsible for paying a pro rata share (based on the number of licensees for such Penn Patent Rights) of documented Historical Patent Costs and Ongoing Patent Costs (as such terms are defined in Section 6.2) for Penn Patent Rights B, Penn Patent Rights C and Manufacturing Patent Rights covering a Reserved Capsid for each Indication following Penn’s receipt of a Capsid Notice.
|
2.5.3
|
Updates Regarding Next Generation Capsid
. With regard to a Reserved Capsid or a Next Generation Capsid for a Designated Product, Penn will keep Licensee apprised, on a confidential basis, of material regulatory communications or other interactions to or from the FDA or EMA, which Penn is aware, with respect to such Next Generation Capsid, including any material safety issues with respect to any of the foregoing, in each case, to the extent such disclosure is not prohibited by a Third Party arrangement to which Penn is a party.
|
2.6
|
Designated Product Selection.
For each Indication within [***] of the completion of the DTP of an AAV gene therapy product for such Indication and the receipt by Licensee of the Research Results with respect to such Indication, Licensee will provide written notice to Penn of its selection of the AAV capsid and the transgene sequence for such Pre-Designation Product for further development by Licensee, at which time such Pre-Designation Product (including such AAV capsid and transgene sequence) will become a Designated Product. With respect to the AAV capsid to be used in the Designated Product for each Indication, Licensee may designate that it will use [***].
|
2.7
|
[
***].
|
2.7.1
|
[***].
|
2.7.2
|
[***].
|
2.7.3
|
[***].
|
2.7.4
|
[***
]
.
|
2.8
|
Expanded Collaboration.
[***].
|
2.9
|
Program Failure
. Should any Licensed Product development program for any Indication fail at a key decision point during the Research Program, as such failure is defined in the Research Plan, and a decision is subsequently made by the Licensee to discontinue further development of the Research Program with respect to such Indication (“
Failed Indication
”), any remaining Research Support Amount allocated for the Failed Indication program pursuant to the then-current agreed budget for the Research Program (minus wind-down and non-cancellable expenses with respect to the activities under the research plan for such Failed Indication) will be reallocated to activities to be conducted under the Research Program for the other remaining Indications under the Research Program. Such Failed Indication will be removed promptly from the Indication definition of the Agreement, with written confirmation of such termination of rights promptly provided by Licensee to Penn (“
Failed Indication Notice
”). In addition, Penn’s obligations pursuant to the Limited Exclusivity Covenant in Section 2.7 shall terminate as of the date of such Failed Indication Notice; and any licenses and rights granted by Amicus to Penn under the Amicus Technology with respect to such Failed Indication shall also automatically terminate, effective as of the date of the applicable Failed Indication Notice.
|
2.10
|
Data Ownership
. All data generated by Penn under a Research Program shall be owned by Penn including all rights, title and interest (“
Penn Data
”). All data generated by Licensee under a Research Program shall be owned by Licensee (“
Licensee Data
”). For the avoidance of doubt, Penn Data will constitute Research Results and Licensed Know-How and will be included within the scope of the License.
|
2.11
|
Governance
.
|
2.11.1
|
Joint Steering Committee
.
|
(a)
|
Formation; Composition
. Within sixty (60) days of the Effective Date, the Parties will establish a joint steering committee (the “
Joint Steering Committee
” or “
JSC
”) comprised of three (3) representatives from each Party with sufficient seniority within the applicable Party to make decisions arising within the scope of the JSC’s responsibilities. The JSC may change its size from time to time by mutual consent of its members, provided that the JSC will consist at all times of an equal number of representatives of each of Penn and Licensee. Each Party may replace its JSC representatives at any time upon written notice to the other Party.
|
(b)
|
Specific Responsibilities
. The JSC will:
|
(i)
|
oversee the Research Program;
|
(ii)
|
on or before November 1 of each year, approve an updated budget in accordance with Section 2.3.1;
|
(iii)
|
approve any amendments to the Research Plan (including any changes to the budget that are greater than the higher of [
***
];
|
(iv)
|
determine whether Penn or Licensee will contract directly with subcontractors;
|
(v)
|
establish appropriate reporting procedures for the Research Program, including the scope and content of reports to be provided by each Party to the other Party (specifically for Penn under Section 2.2.4) and in order to provide Licensee with sufficient information regarding the Research Results for each Indication to allow Licensee to select a Designated Product pursuant to Section 2.6;
|
(vi)
|
endeavor to resolve any disagreement between the Parties relating to the Research Program or Research Plan; and
|
(vii)
|
establish such additional subcommittees as it deems necessary to achieve the objectives and intent of the Research Program.
|
(c)
|
Reporting
. Each Party shall keep the JSC informed on the status and progress of the activities under the Research Program then currently ongoing under a Research Plan, including delivering quarterly written updates of its progress under the Research Plan to the JSC at least one (1) week in advance of each JSC meeting.
|
(d)
|
Meetings
. During the performance of the Research Plan by Penn, the JSC will meet at least quarterly. Following the completion of Penn’s performance of the Research Plan, the Parties may agree to meet to discuss items previously addressed by the JSC. The JSC may meet in person, by videoconference or by teleconference. Notwithstanding the foregoing, at least two (2) meetings per Calendar Year will be in person unless the parties mutually agree in writing to waive such requirement. In-person JSC meetings will be held at locations alternately selected by Penn and by Licensee; provided, however, that Licensee shall reimburse Penn for its JSC representatives’ reasonable out-of-pocket travel costs in connection with attending such in-person JSC meeting at a location other than in Philadelphia. Meetings of the JSC will be effective only if at least one representative from each Party is present or participating in such meeting. The JSC shall keep accurate minutes of its deliberations which shall record all proposed decisions and all actions recommended or taken. The secretary of the JSC (as appointed by the members of the JSC) shall be responsible for the preparation of draft minutes. Draft minutes shall be sent to all members of the JSC within ten (10) working days after each meeting and shall be approved, if appropriate, at the next meeting. All records of the JSC shall at all times be available to both Penn and Licensee.
|
(e)
|
Decision-Making
. The representatives from each Party on the JSC will have, collectively, one (1) vote on behalf of that Party, and all decision making will be by unanimous consent of both Parties. If the JSC is unable to reach agreement on any issue or matter within the scope of the JSC’s decision-making authority, such disputed matter will be escalated to Licensee’s Chief Executive Officer and Penn’s Dean of Medicine or his designee, for discussion in good faith.
|
2.11.2
|
Joint Intellectual Property Committee
.
|
(a)
|
Formation; Composition
. Within thirty (30) days of the Effective Date, the Parties will establish a joint intellectual property oversight committee (the “
Joint Intellectual Property Committee
” or “
JIPC
”) comprised of an equal number of representatives from each Party. The JIPC may change its size from time to time by mutual consent of its members, provided that the JIPC will consist at all times of an equal number of representatives of each of Penn and Licensee, with at least one representative of Penn from the Penn Center for Innovation. Each Party may replace its JIPC representatives at any time upon written notice to the other Party.
|
(b)
|
Specific Responsibilities
. The JIPC will discuss and make recommendations with respect to the intellectual property activities of the Parties related to Licensed Product research and development under the Research Plan in a manner that is consistent with the other terms of this Agreement, specifically with respect to the prosecution, maintenance, defense and enforcement of the Penn Patent Rights A and Joint Patent Rights.
|
(c)
|
Meetings
. The JIPC will meet at twice annually, unless the Parties mutually agree in writing to a different frequency. The JIPC may meet in person, by videoconference, or by teleconference. In-person JIPC meetings will be held at locations alternately selected by Penn and by Licensee; provided, however, that Licensee shall reimburse Penn for its JIPC representatives’ costs in connection with attending such in-person JSC meeting at a location other than Penn. Meetings of the JIPC will be effective only if at least one representative of each Party is present or participating in such meeting.
|
(d)
|
Decision-Making
. The representatives from each Party on the JIPC will have, collectively, one (1) vote on behalf of that party, and all decision making will be by unanimous consent by the Parties. Disputes at the JIPC will be referred to the JSC for resolution.
|
2.11.3
|
Scope of Authority
.
|
3.1
|
Grant of License
. Subject to the terms and conditions of this Agreement, Penn hereby grants to Licensee (the below rights under (a) through (c), the “
License
”).
|
3.2
|
Joint Patent Rights
.
Each Party hereby grants to the other Party a non-exclusive, world-wide, royalty-free, fully paid up, perpetual, irrevocable right and license, with the right to freely sublicense under the Joint Patent Rights, to make, have made, use sell, offer for sale and products and services other than products and services for the Indications in the Field of Use.
|
3.3
|
Research License to Penn
. Licensee will grant to Penn a non-exclusive, non-transferable, non-sublicensable license (a) under [***] the “
Amicus Technology
”) solely for purposes of performing Penn’s obligations under a Research Program in accordance with the Research Plan and the terms of this Agreement and (b) under (i) the Licensee Data and (ii) new inventions reduced to practice by Licensee in the performance of the Research Program, in the case of each of (i) and (ii), to the extent Controlled by Amicus and solely during the Exclusivity Period and solely for purposes of performing internal, non-commercial research in the Wilson Lab. Notwithstanding the foregoing, Amicus Technology expressly excludes any Joint Patent Rights. For clarity, internal, non-commercial research includes performance of activities funded by a government entity or non-commercial Third Party (so long as such non-commercial third party does not obtain any commercial right in or to any data, results, inventions or other intellectual property arising in connection with the relevant funded activities). Amicus Technology will remain the exclusive property of Licensee. Penn shall use the Amicus Technology solely in the conduct of the Research Program in accordance with the Research Plan and the term of this Agreement. Penn shall not reverse engineer, decompile or disassemble any Amicus Technology, nor attempt or assist any Third Party to do the foregoing. Amicus Technology is provided “as is” with no warranty, express, implied or statutory, including without limitation warranties of merchantability, title, non-infringement, exclusivity or fitness for a particular purpose.
|
3.4
|
Retained Rights
. Notwithstanding the License,
Penn retains the right under the Penn Patent Rights to (a) conduct educational, research and clinical / patient care activities itself (including sponsored research) and (b) authorize non-commercial third parties to conduct education, non-commercial research and clinical / patient activities, in each case of subpart (a) and (b) related to the Indications in the Field of Use; provided however that Penn shall not have the right to use or authorize the use of any Licensed Product for an Indication that is under active clinical testing or being sold by Licensee in the conduct of clinical or patient care activities without Licensee’s consent.
|
3.5
|
U.S. Government Rights
. The License is expressly subject to all applicable provisions of any license to the United States Government executed by Penn and is subject to any overriding obligations to the United States Federal Government under 35 U.S.C. §§200-212, applicable governmental implementing regulations, and the U.S. Government sponsored research agreement or other guidelines, including that products that result from intellectual property funded by the United States Federal Government that are sold in the United States be substantially manufactured in the United States. If so requested by Licensee, Penn shall reasonably cooperate with and assist Licensee to seek and obtain a waiver from the appropriate Regulatory Authorities with respect to such manufacturing requirement.
|
3.6
|
Grant of Sublicense by Licensee
.
|
3.6.1
|
Penn grants to Licensee the right to grant and authorize sublicenses, in whole or in part, under the License (each, a “
Sublicense
”) subject to the terms and conditions of this Agreement and specifically this Section 3.6. The term Sublicense shall include any grant of rights under the License by a Sublicensee to any downstream Third Party to develop, manufacture, use or sell a Licensed Product, such downstream Third Party shall also be considered a Sublicensee for the purposes of this Agreement.
|
3.6.2
|
Licensee will have the right to extend any and all of its rights under this Agreement to its Affiliate (subject to such Affiliate agreeing in writing with Licensee to be bound by the terms and conditions of this Agreement to the extent applicable to such Affiliate) without the consent of Penn; provided that Licensee will be responsible for the conduct of any such Affiliate under the Agreement to the same extent as if such activities had been undertaken by Licensee itself.
|
3.6.3
|
Licensee will have the right to grant Sublicenses to a Third Party (and their Affiliates), without the consent of Penn. For clarity, except for Sublicenses granted to Service Provider Sublicensees pursuant to Section 3.6.4 below, this provision permits only a single-tier of sublicensing to a Third Party (and its Affiliates) for Sale of a Licensed Product.
|
3.6.4
|
Licensee, Sublicensee and each of their respective Affiliates may also, without Penn’s consent, engage Third Party service providers (and grant Sublicenses within the scope of the License to such Persons) solely to perform activities for the benefit of or on behalf of Licensee or such Sublicensee or Affiliate, as the case may be (each a “
Service Provider Sublicensee
”). Licensee shall remain responsible to Penn for all activities of such Service Provider Sublicensee to the same extent as if such activities had been undertaken by Licensee itself.
|
3.6.5
|
Each Sublicense Document will (a) be issued in writing, (b) to the extent applicable, include all of the rights of Penn and require the performance of obligations due to Penn (and, if applicable, the U.S. Government under 35 U.S.C. §§200-212) contained in this Agreement and (c) to the extent applicable, include the following terms and conditions:
|
(a)
|
Reasonable record keeping, audit and reporting obligations sufficient to enable Licensee and Penn to reasonably verify the payments due to Penn as a result of such Sublicense and to reasonably monitor such Sublicensee’s progress in developing and/or commercializing Licensed Product.
|
(b)
|
Infringement and enforcement provisions that do not conflict with the restrictions and procedural requirements imposed on Licensee and do not provide greater rights to Sublicensee than as provided in Section 6.3.
|
(c)
|
Confidentiality provisions with respect to Confidential Information of Penn provided to a Sublicensee consistent with the obligations on Licensee in Article 8 of this Agreement.
|
(d)
|
Covenants by Sublicensee that are equivalent to those made by Licensee in Section 8.3.
|
(e)
|
A requirement of indemnification of Penn by Sublicensee that is equivalent to the indemnification of Penn by Licensee under Section 9.1 of this Agreement.
|
(f)
|
A requirement of obtaining and maintaining insurance by Sublicensee that is equivalent to the insurance requirement of Licensee under Section 9.2 of this Agreement, including coverage under such insurance of Penn as provided in Section 9.2.
|
(g)
|
Restriction on use of Penn’s names etc. consistent with Section 11.4 of this Agreement.
|
(h)
|
A requirement of antidiscrimination by Sublicensee no less stringent than that provided in Section 11.5 of this Agreement.
|
(i)
|
A requirement that Penn is a third party beneficiary of such Sublicense solely with respect to the rights of Penn and the performance obligations owed to Penn as required hereunder.
|
3.6.6
|
Within thirty (30) days after of the execution of a Sublicense Document, Licensee shall provide a complete and accurate copy of such Sublicense Document (which may be redacted with respect to matters unnecessary to show compliance herewith, provided that in no event will any financial information be redacted) to Penn, in the English Language. Penn’s receipt of a Sublicense Document, however, will constitute neither an approval nor disapproval of the Sublicense Document nor a waiver of any right of Penn or obligation of Licensee under this Agreement. Notwithstanding the foregoing, upon Penn’s request, Licensee will provide an unredacted copy of any Sublicense Document to Penn’s outside counsel to confirm compliance herewith, and such outside counsel shall not provide such Sublicense Document to Penn.
|
3.7
|
No Implied License.
Each Party acknowledges that the rights and licenses granted in this Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party. All rights with respect to any know-how, patent or other intellectual property right rights that are not specifically granted herein are reserved to the owner thereof.
|
4.1
|
Payments
|
4.1.1
|
Issue Fee.
In partial consideration of the rights and licenses granted to Licensee under this Agreement, within [***] following the Effective Date, Licensee shall pay Penn a non-refundable and non-creditable license issue fee of Seven Million US Dollars ($7,000,000). Such payment will be made by wire transfer of immediately available funds into the account specified in Section 4.5.
|
4.1.2
|
Alliance Management Fee
. During the Research Term, Licensee shall pay the Penn Center for Innovation an annual alliance management fee of [***] per year within [***] following the Effective Date and each one-year anniversary thereof. For clarity, the amount of the alliance management fee will be paid only once per year (not once per Indication) and will not exceed [***] in any year and would not be payable in any year in which a License Maintenance Fee is also payable.
|
4.1.3
|
License Maintenance Fee
. Following expiration of the Research Term and until the expiration of the first Royalty Term in the first Major Market for a Licensed Product, Licensee shall pay Penn a non-refundable and annual maintenance fee of [***] for the first and second year after the anniversary of the Research Term expiration date and [***] for the third year after the anniversary of the Research Term expiration date and on each anniversary thereafter (“
License Maintenance Fee
”). The License Maintenance Fee payment obligation shall only be creditable against royalties owed to Penn in the year such License Maintenance Fee was paid (there shall be no carry forward credit on License Maintenance Fees paid). For clarity, the amount of the License Maintenance Fee will be paid only once per year (not once per Indication).
|
4.1.4
|
New Indication Option Payment.
Within [***] following Licensee’s exercise of the New Indication Options, Licensee will pay to Penn a non-refundable, non-creditable payment in the amount of [***] by wire transfer of immediately available funds (“
New Indication Option Fee
”) pursuant to Section 4.5 below.
|
4.2
|
Milestone Payments.
|
4.2.1
|
Development Milestones
.
|
(a)
|
As additional consideration for the License, Licensee will pay Penn the following milestone payments (each, a “
Development Milestone Payment
”) upon the achievement of the first Licensed Product to achieve the corresponding milestone for each Indication (each, a “
Development Milestone
”), whether achieved by Licensee or an Affiliate or Sublicensee. Licensee shall promptly notify Penn in writing of the achievement of any such Development Milestone and Licensee shall pay Penn in full the corresponding Development Milestone Payment within [***] days of such achievement. For clarity, each Development Milestone Payment is non-refundable, non-creditable and is not an advance against Royalties due to Penn or any other amounts due to Penn.
|
Development Milestone (payable once per Indication)
|
Milestone Payment (in U.S. dollars)
|
[***]
|
$[***]
|
[***]
|
$[***]
|
[***]
|
$[***]
|
[***]
|
$[***]
|
[***]
|
$[***]
|
[***]
|
$[***]
|
Total Development Milestones per Indication
|
$[
***
]
|
(b)
|
Each time a Development Milestone [***] in the table above is achieved for a Licensed Product for an Indication, then any other Development Milestone Payments with respect to earlier Development Milestones (i.e., Development Milestones [***] in the table above, as applicable) for that Indication that have not yet been paid will be due and payable together with the Development Milestone Payment for the relevant Development Milestone that is actually achieved. If Development Milestone [***] is achieved prior to the achievement any of Development Milestones [***], then Milestone Payments for Development Milestones [***] shall be due to the extent not previously paid.
|
4.2.2
|
Commercial Milestone Payments
.
|
(a)
|
As additional consideration for the License, Licensee will pay Penn the following commercial milestone payments (each, a “
Commercial Milestone Payment
”) upon the achievement of the corresponding milestone (each, a “
Commercial Milestone
”), whether achieved by Licensee or an Affiliate or Sublicensee, or a combination of Licensee, Affiliate or Sublicensee, when cumulative worldwide Net Sales of Licensed Product(s) for an Indication reach the respective thresholds indicated below. Licensee shall notify Penn in writing of the achievement of any such Commercial Milestone within [***] following [***] in which such Commercial Milestone is achieved and Licensee shall pay Penn in full the corresponding Commercial Milestone Payment together with such notice. For clarity, each Commercial Milestone Payment is non-refundable, non-creditable and is not an advance against Royalties due to Penn or any other amounts due to Penn.
|
Commercial Milestone
(payable once per Indication)
|
Milestone Payment
|
Cumulative Net Sales of Licensed Product for an Indication reaches $[***]
|
$[
***]
|
Cumulative Net Sales of Licensed Product for an Indication reaches $[***]
|
$[***]
|
Cumulative Net Sales for Licensed Product for an Indication reaches $[***]
|
$[***]
|
Total Commercial Milestone Payments to Penn for each Indication
|
$[
***
]
|
4.3
|
Royalties
.
|
4.3.1
|
Royalty
. As further consideration for the License, on a Licensed Product-by-Licensed Product basis during the applicable Royalty Period Licensee shall pay to Penn a non-refundable, non-creditable royalty on worldwide Net Sales of Licensed Product (“
Royalty
”) as set forth below:
|
Annual Worldwide Net Sales of a Licensed Product
|
Royalty Rate
|
Less than $[***]
|
[***]
|
Greater than or equal to $[***] and less than or equal to $[***]
|
[***]
|
Greater than $[***]
|
[***]
|
4.3.2
|
Royalty Term
. Licensee’s obligation to pay Penn the Royalty will continue on a country-by-country and Licensed Product-by-Licensed Product basis from the date of First Commercial Sale of such Licensed Product in a country until the latest of (a) the expiration or abandonment of the last Valid Claim within the Penn Patent Rights covering such Licensed Product in such country, (b) [***] after First Commercial Sale of such Licensed Product in such country, (c) the expiration of the Regulatory Exclusivity with respect to such Licensed Product; provided that if both the [***] period described in subpart (b) and the applicable Regulatory Exclusivity described in subpart (c) have both expired and there are only pending Valid Claims, but not any issued Valid Claim, in such country covering such Licensed Product on the date that is [***] after the First Commercial Sale of such Licensed Product in such country, the royalty term with respect to such Licensed Product shall expire on such date (such royalty period, the “
Royalty Period
”).
|
4.3.3
|
Royalty Reductions
.
|
(a)
|
[***].
|
(b)
|
[***].
|
(i)
|
[***]
.
|
(ii)
|
[***]
.
|
(iii)
|
[***]
.
|
(iv)
|
[***]
.
|
4.3.4
|
Calculations
. Licensee must pay Royalties owed to Penn on a Calendar Quarter basis on or before the following dates:
|
(a)
|
[***] for any Sales that took place on or before the last day of the Calendar Quarter ending December 31, of the prior Calendar Year;
|
(b)
|
[***] for any Sales that took place on or before the last day of the Calendar Quarter ending March 31 of such Calendar Year;
|
(c)
|
[***] for any Sales that took place on or before the last day of the Calendar Quarter ending June 30 of such Calendar Year; and
|
(d)
|
[***] for any Sales that took place on or before the last day of the Calendar Quarter ending September 30 of such Calendar Year.
|
4.4
|
Penn Sublicense Income
.
|
4.4.1
|
On a Licensed Product-by-Licensed Product basis, Licensee will pay to Penn the following percentage of Sublicense Income (“
Penn Sublicense Income
”) received by Licensee from a Sublicensee:
|
Stage in Licensed Product development for the applicable Indication at which Sublicense is granted by Licensee
|
Percent of Sublicense Income payable to Penn
|
Prior to [***] for the first Licensed Product for such Indication
|
[***
|
After [***] for the first Licensed Product for such Indication and prior to [***] for the first Licensed Product for such Indication
|
[***]
|
After [***] for the first Licensed Product for an Indication
|
[***]
|
4.4.2
|
Licensee will make such payment to Penn on or before the following dates:
|
(a)
|
[***] for any Sublicense Income received by Licensee on or before the last day of the Calendar Quarter ending December 31, of the prior Calendar Year;
|
(b)
|
[***] for any Sublicense Income received by Licensee on or before the last day of the Calendar Quarter ending March 31 of such Calendar Year;
|
(c)
|
[***] for any Sublicense Income received by Licensee on or before the last day of the Calendar Quarter ending June 30 of such Calendar Year; and
|
(d)
|
[***] for any Sublicense Income received by Licensee on or before the last day of the Calendar Quarter ending September 30 of such Calendar Year.
|
4.5
|
Mode of Payment and Currency
. All payments to Penn hereunder shall be made by deposit of USD in the requisite amount to the “The Trustees of the University of Pennsylvania” and will be made by delivery to any one of the following:
|
By ACH/Wire:
|
[***]
|
[***] (domestic wires)
|
[***]
|
(international wires only)
|
Account Number:
[***]
|
|
By ACH/Wire:
|
By Check (direct mail):
|
By Check (lockbox):
|
[***]
|
The Trustees of the
|
The Trustees of the
|
[***] (domestic wires)
|
University of Pennsylvania
|
University of Pennsylvania
|
[***]
|
c/o Penn Center for Innovation
|
c/o Penn Center for Innovation
|
(international wires only)
|
Attention: Financial
|
PO Box 785546
|
Account Number:
[***]
|
Coordinator
|
Philadelphia, PA 19178-5546
|
|
3160 Chestnut Street, Suite 200
Philadelphia, PA 19104-6283
|
|
4.6
|
Royalty and Penn Sublicense Income Reports
. Within [***] after the end of each Calendar Quarter, Licensee shall deliver to Penn a report (“
Financial Report
”) setting out sufficient details necessary to calculate the Royalty and Penn Sublicense Income due under this Article 4 for such Calendar Quarter, including:
|
4.6.1
|
Number of each Licensed Product Sold by Licensee, its Affiliates and Sublicensees in each country, the corresponding name of each such Licensed Product;
|
4.6.2
|
Gross sales, Net Sales of each Licensed Product made by Licensee, its Affiliates and Sublicensees;
|
4.6.3
|
Royalties due for the applicable period pursuant to Section 4.3;
|
4.6.4
|
Sublicense Income due for the applicable period pursuant to Section 4.4 and the calculation of Penn Sublicense Income;
|
4.6.5
|
The method and currency exchange rates (if any) used to calculate the Royalties and Penn Sublicense Income;
|
4.6.6
|
[***];
|
4.6.7
|
[***]; and
|
4.6.8
|
Date of First Commercial Sale of each Licensed Product in the United States (this need only be reported in the first royalty report following such First Commercial Sale in the United States).
|
4.7
|
Late Payments
. In addition to any other remedies available to Penn, including the right to terminate this Agreement, any failure by Licensee to make a payment within [***] after the date when due shall obligate Licensee to pay computed interest, the interest period commencing on the due date and ending on the actual payment date, to Penn at a rate per annum equal to [***], or the highest rate allowed by Law, whichever is lower.
|
4.8
|
Default Payment
. In the event of default in payment of any payment owing to Penn under the terms of this Agreement, and if it becomes necessary for Penn to undertake legal action to collect said payment, Licensee shall pay reasonable, documented legal fees and costs incurred in connection therewith.
|
4.9
|
Accounting
. Each Party shall calculate all amounts, and perform other accounting procedures required, under this Agreement and applicable to it in accordance with GAAP.
|
4.10
|
Books and Records
. Licensee will keep accurate books and records of all Licensed Products developed, manufactured, used or sold and all Sublicenses entered into by Licensee with respect to Penn Patent Rights. Licensee will preserve these books and records for at least [***] from the date of the Financial Report to which they pertain. Upon reasonable notice, not less than [***] days prior to the proposed date of review, books and records pertaining to the calculation of any Milestones, Royalties and Penn Sublicense Income due to Penn under this Agreement will be made reasonably available and will be open to examination by up to two (2) representatives or agents of Penn reasonably acceptable to Licensee (and to the extent such are not employees of Penn each of whom has executed an appropriate confidentiality agreement reasonably acceptable to Licensee that requires the representative or agent to keep any information learned by it confidential except as needed to report its audit conclusions to Penn) for no longer than one (1) business day during regular office hours to determine the accuracy of such books and records and assess Licensee’s compliance with the terms of this Agreement, provided that Licensee shall not have an obligation to provide such access more than once in any given twelve (12) month period nor more than [***] after the date of any record to be audited.
|
4.11
|
Audits
. Penn, at its own cost, through an independent auditor reasonably acceptable to Licensee (and who has executed an appropriate confidentiality agreement reasonably acceptable to Licensee that requires the auditor to keep any information learned by it confidential except as needed to report its audit conclusions to Penn), may inspect and audit the relevant records of Licensee pertaining to the calculation of any Milestones, Royalties and Penn Sublicense Income due to Penn under this Agreement. Licensee shall provide such auditors with access to the records at Licensee’s principal place of business during reasonable business hours. Such access need not be given to any such set of records more often than once each Calendar Year nor more than [***] after the date of any report to be audited. Penn shall provide Licensee with written notice of its election to inspect and audit the records related to the Milestones and Royalties due hereunder not less than [***] prior to the proposed date of review of Licensee’s records by Penn’s auditors. Should the auditor establish any underpayment of Milestones, Royalties or Penn Sublicense Income by Licensee, Licensee shall (a) promptly pay Penn the amount of such underpayment; (b) shall reimburse Penn for the cost of the audit, if such underpayment equals or exceeds [***] of Milestones, Royalties or Penn Sublicense Income paid during the time period audited. If the auditor finds overpayment by Licensee, then Licensee shall have the right to deduct the overpayment from any future milestones or royalties due to Penn by Licensee or, if no such future milestones or royalties are payable, then Penn shall refund the overpayment to Licensee within [***] after Penn receives the audit report. Licensee may designate competitively sensitive information which such auditor may see and review but which it may not disclose to Penn; provided, however, that such designation shall not restrict the auditor’s investigation or conclusions.
|
4.12
|
Taxes
. All payments made by Licensee to Penn under the Agreement shall be made free and clear of and without any deduction for or on account of any Taxes on or with respect to such payments.
|
5.1
|
Development Plan
. Until the First Commercial Sale in a Major Market of the first Licensed Product for each Indication, Licensee shall provide Penn with a development plan for a Licensed Product for such Indication no later than December 1st of each year during the Term, commencing with the Calendar Year after the expiration of the Research Term. The development plan shall include a timeline for material clinical activities to be conducted by Licensee, its Affiliates and Sublicensees to support obtaining Regulatory Approvals for a Licensed Product in the Major Markets in each Indication.
|
5.2
|
Clinical
. Licensee will consider in good faith using Penn as a study site for one or more Clinical Studies for a Licensed Product where Penn can reasonably demonstrate that Penn’s capabilities and costs are reasonably comparable to other potential study sites. If Penn (in its sole discretion) is willing and able to conduct a Clinical Study for a Licensed Product developed under the Research Program, the Parties will negotiate a separate clinical trial agreement and a separate clinical trial budget prior to initiation of such clinical trial. For clarity, any Clinical Study funding by Licensee shall be separate and in addition to the Research Support Amount.
|
5.3
|
Commercialization
. As between the Parties, Licensee will have sole responsibility for and sole decision-making over all commercialization activities of the Licensed Products for the Indications in the Field of Use, and will be solely responsible for the associated costs of such commercialization activities.
|
5.4
|
Manufacturing
. Except as otherwise provided in this Agreement or in the Research Plan, as between the Parties, Licensee will have responsibility for and decision-making authority over all manufacturing activities and associated costs for the clinical development (including cGMP manufacturing for clinical trials) and commercialization of the Licensed Products for the Indications in the Field of Use post-DTP for each such Licensed Product. Penn will have sole responsibility and sole decision-making authority over manufacturing activities for pre-clinical manufacturing, at Licensee’s cost.
|
5.5
|
Regulatory
.
|
5.5.1
|
As between the Parties, Licensee will have responsibility for and decision-making over regulatory activities for the Licensed Products for the Indications in the Field of Use. As between the Parties, Licensee will have the right to conduct all communications with Regulatory Authorities, including all meetings, conferences and discussions (including advisory committee meetings), with regard to Licensed Products for the Indications in the Field of Use. Licensee will lead and have control over preparing and submitting all INDs, BLAs and other material regulatory filings related to the Licensed Products for the Indications in the Field of Use, including all applications for Regulatory Approval, provided, however, that Licensee shall provide Penn with copies of all such applications for Regulatory Approval prior to submission. As between the Parties, Licensee will own any and all applications for Regulatory Approvals (including INDs), Regulatory Approvals, and other regulatory filings related to the Licensed Products for the Indications in the Field of Use which will be held in the name of Licensee or its designees.
|
5.5.2
|
At Licensee’s reasonable request and expense, Penn (through Dr. Wilson and other Wilson Lab personnel) shall reasonably cooperate with and assist Licensee (or its designee) in connection with interactions with Regulatory Authorities relating to Licensed Products for the Indications in the Field of Use. In addition, Licensee will keep Penn reasonably informed of the progress of such regulatory interactions and, upon request but not more than twice per Calendar Year, Licensee will provide to Dr. Wilson (or another designated Wilson Lab personnel), on a confidential basis, a copy of any material regulatory filings or correspondence to or from the FDA or EMA with respect to a Licensed Product for an Indication. Licensee will consider any reasonable comments provided on a timely basis by Dr. Wilson (or such Wilson Lab personnel).
|
5.6
|
General Diligence
. Licensee (itself and/or through its Affiliates or Sublicensees) shall use Commercially Reasonable Efforts to actively develop and, following Regulatory Approval, to commercialize, in the Major Markets one Licensed Product for each Indication in the Field of Use.
|
5.7
|
Structured Development Diligence Events.
Licensee shall to achieve each of the following Diligence Events for each Indication by the corresponding Achievement Date:
|
5.8
|
Licensee may extend any Achievement Date for a Diligence Event (and all subsequent Diligence Events) by [***] increments, but not more than [***] per Indication, by making a [***] payment per extension to Penn prior to the expiration of the Achievement Date for such Diligence Event. [***].
|
5.9
|
Progress Reports
.
|
5.9.1
|
After performance of the Research Plan by Penn but prior to the First Commercial Sale of a Licensed Product for an Indication, Licensee on an annual basis, but in no event later than June 1st of each Calendar Year, shall submit to Penn a progress report (each, a “
Progress Report
”) summarizing Licensee’s (and any Affiliates’ and Sublicensees’) material activities related to the development of all Licensed Products for each Indication directed to obtaining of Regulatory Approvals necessary for commercialization of Licensed Products in the Major Markets.
|
5.9.2
|
Each Progress Report must include all of the following for each annual period:
|
(a)
|
Update on the status of material pre-clinical work and Clinical Studies involving a Licensed Product, as well as the status of any IND and/or BLA filings for a Licensed Product; and
|
(b)
|
Anticipated dates for receipt of Regulatory Approval for a Licensed Product in the Major Markets.
|
6.1
|
Patent Filing Prosecution and Maintenance
.
|
6.1.1
|
Penn will use diligent efforts to file, and thereafter prosecute in good faith and maintain, a Patent Right(s), which would be included in Penn Patent Rights A, claiming the Designated Product for each Indication and the use of such Designated Product for the Indication. Penn Patent Rights will be held in the name of Penn and obtained with counsel selected by Penn and reasonably acceptable to Licensee (“
Patent Counsel
”). Penn shall control all actions and decisions with respect to the filing, prosecution and maintenance of Penn Patent Rights A and Joint Patent Rights in close coordination with Licensee via discussions at the JIPC and, in any event, Penn will consider any reasonable comments or suggestions by Licensee with respect to same; provided, however, that with respect to Penn Patent Rights A claiming solely a Designated Product applicable to the Indications in the Field of Use (“
Product-Specific Patent Rights
”) and Joint Patent Rights, Penn shall have an obligation to consider in good faith and implement any reasonable comments provided by Licensee. Penn will instruct Patent Counsel to copy Licensee on all correspondence related to Penn Patent Rights A and Joint Patent Rights (including copies of each patent application, office action, response to office action, request for terminal disclaimer, and request for reissue or reexamination of any patent or patent application) and to interact with Licensee with respect to the preparation, filing, prosecution and maintenance of Penn Patent Rights A and Joint Patent Rights. Penn has the right to take action to preserve rights and minimize cost whether or not Licensee has commented, and will use all reasonable efforts to not allow any Penn Patent Rights A and Joint Patent Rights for which Licensee is licensed and is underwriting the costs to lapse or become abandoned without Licensee’s written authorization under this Agreement, except for filing of continuations, divisionals, or the like that substitute for the lapsed application, provided that, Penn shall have no requirement to file, prosecute, or maintain Penn Patent Rights A and Joint Patent Rights if Licensee is not current with the Patent Cost obligations as set forth in this Agreement. For the purposes of this Agreement, “maintenance” of the Penn Patent Rights A and Joint Patent Rights includes inter parties patent review proceedings before the USPTO or a similar patent administration outside the US. For further clarity, validity challenges raised in infringement litigation will be handled per Section 6.3, Infringement.
|
6.1.2
|
The Parties shall discuss and agree at the JIPC the countries in which Patents within the Penn Patent Rights A and Joint Patent Rights will be filed. Licensee has the right to request any additional country filing for Penn Patent Rights A and Joint Patent Rights via a written request to Penn ninety (90) days prior to the deadline set by the patent office in the territory in which filing is to take place (“
Prosecution Request
”). The absence of a given Prosecution Request by such deadline will be considered an election not to secure the Patent Rights associated with the specific phase of patent prosecution in such territory, and such patent application(s) and patent(s) (“
Carve-Out Patent Rights
”) will not be part of Penn Patent Rights and therefore not subject to this Agreement, including the License, and Licensee will have no further rights or license to them.
|
6.1.3
|
For Penn Patent Rights B, Penn Patent Rights C and Manufacturing Patent Rights, Penn will instruct Patent Counsel to copy Licensee on all correspondence (including copies of each patent application, office action, response to office action, request for terminal disclaimer, and request for reissue or reexamination of any patent or patent application), to interact with Licensee with respect to the preparation, filing, prosecution and maintenance, and to consider any reasonable comments or suggestions by Licensee with respect to same.
|
6.1.4
|
Licensee shall also have the right, on a Penn Patent Right-by-Penn Patent Right basis, to elect not to continue to reimburse Penn for the Patent Costs with respect to any Penn Patent Right(s), which election may be made by Licensee upon sixty (60) days prior written notice to Penn. If Licensee makes such election and delivers such notice to Penn, following the expiration of such sixty (60) day period, Licensee shall have no further obligation to pay Ongoing Patent Costs with respect to any Penn Patent Rights identified in such a notice and such Patents shall thereafter be excluded from the Penn Patent Rights.
|
6.2
|
Patent Costs
.
|
6.2.1
|
Subject to Section 6.2.3, on the Effective Date, Licensee will reimburse Penn for all documented out-of-pocket costs for the filing, prosecution and maintenance of Penn Patent Rights and Joint Patent Rights, including all accrued and documented attorney fees, expenses, official and filing fees (“
Patent Costs
”), incurred prior to the Effective Date or the date at which such Patent Rights are added to the License (as applicable), which have not otherwise been reimbursed by other licensees of such Penn Patent Rights (“
Historic Patent Costs
”).
|
6.2.2
|
Licensee will bear all Patent Costs incurred during the Term (“
Ongoing Patent Costs
”). For Penn Patent Rights licensed by Penn to more than one licensee, Licensee shall be responsible for payment to Penn of a pro rata share of such documented Ongoing Patent Costs based on the number of licensees for such Penn Patent Rights. No later than sixty (60) days prior to the end of each Calendar Year during the Term, Penn shall provide to Licensee, a good faith estimate and budget for the Ongoing Patent Costs anticipated to be incurred for the next Calendar Year and, to the extent applicable, Licensee’s proportionate share of such Ongoing Patent Costs.
|
6.2.3
|
Licensee shall pay in advance the Patent Counsel’s estimated costs for undertaking material patent actions before Penn authorizes the Patent Counsel to proceed (“
Advance Payment
”). Notwithstanding whether Licensee makes an Advance Payment for any patent action, Licensee shall bear its pro rata share (based on the based on the number of licensees for such Penn Patent Rights) of all Patent Costs incurred during the Term and shall pay such amounts within [***] of receipt of invoice for such patent actions. For clarity, the term “Patent Costs” means and includes Historic Patent Costs and Ongoing Patent Costs.
|
6.3
|
Infringement
.
|
6.3.1
|
If either Party believes that an infringement by a Third Party with respect to any Penn Patent Right is occurring or may potentially occur, the knowledgeable Party will provide the other Party with (a) written notice of such infringement or potential infringement and (b) evidence of such infringement or potential infringement (the “
Infringement Notice
”). During the period in which, and in the jurisdiction where, Licensee has exclusive rights under this Agreement, subject to Licensee’s right to institute suit for patent infringement pursuant to Section 6.3.2 if infringing activity of potential commercial significance has not been abated within [***] following the date the Infringement Notice for such activity was provided, neither Penn or Licensee will notify such a Third Party (including the infringer) of infringement or put such Third Party on notice of the existence of Penn Patent Rights without first obtaining the written consent of the other Party. If Licensee puts such infringer on notice of the existence of any Penn Patent Right without the prior written consent of Penn prior to the expiration of such [***], then Licensee’s right to initiate a suit under Section 6.3.2 below will terminate immediately without the obligation of Penn to provide notice to Licensee. Both Penn and Licensee will use their diligent efforts to cooperate with each other to terminate any such infringement without litigation.
|
6.3.2
|
If infringing activity of potential commercial significance has not been abated within [***] following the date the Infringement Notice for such activity was provided, then during the period in which, and in the jurisdiction where, Licensee is the sole licensee for certain Penn Patent Rights A and the infringement is a competing product to a Licensed Product, Licensee may institute suit for patent infringement of such Penn Patent Rights A against the infringer. Penn may voluntarily join such suit at its own expense, but may not thereafter commence suit against the infringer for the acts of infringement that are the subject of Licensee’s suit or any judgment rendered in such suit. If in a suit initiated by Licensee, Penn is involuntarily joined other than by Licensee, then Licensee will pay any documented costs incurred by Penn arising out of such suit, including any documented legal fees of counsel that Penn selects and retains to represent it in the suit. Licensee shall be free to enter into a settlement, consent judgment or other voluntary disposition, provided that any settlement, consent judgment or other voluntary disposition that (i) limits the scope, validity or enforcement of Penn Patent Rights A or (ii) admits fault or wrongdoing on the part of Penn must be approved in advance by Penn in writing (such approval not to be unreasonably withheld or delayed). Licensee’s request for such approval shall include complete copies of proposed settlement documents, a summary of such settlement, and any other information material to such settlement that is reasonably requested by Penn. Penn shall provide Licensee notice of its approval or denial within thirty (30) days of any request for such approval by Licensee, provided that (x) in the event Penn wishes to deny such approval, such notice shall include a detailed written description of Penn’s reasonable objections to the proposed settlement, consent judgment, or other voluntary disposition and (y) Penn shall be deemed to have approved of such proposed settlement, consent judgment, or other voluntary disposition in the event it fails to provide such notice within such thirty (30) day period in accordance herewith.
|
6.3.3
|
If, within [***] following the date of a request to do so from Penn, infringing activity of potential commercial significance has not been abated and if Licensee has not brought suit against the infringer, then Penn may institute suit for patent infringement against the infringer. If Penn institutes such suit, then Licensee may not join such suit without the prior written consent of Penn (which consent shall not be unreasonably withheld or delayed) and may not thereafter commence suit against the infringer for the acts of infringement that are the subject of Penn’s suit or any judgment rendered in such suit.
|
6.3.4
|
Notwithstanding Sections 6.3.2 and 6.3.3, in the event that any Penn Patent Rights A are infringed by a Third Party and any of the infringed Penn Patent Rights A are also licensed by Penn to a Third Party, prior to any enforcement action being taken by either Party regarding such infringement, the JIPC shall discuss and determine how to handle such infringement by such Third Party.
|
6.3.5
|
Any recovery or settlement received in connection with any suit will first be shared by Penn and Licensee equally to cover any litigation costs each incurred (to the extent not previously reimbursed) and next shall be paid to Penn or Licensee to cover any litigation costs it incurred in excess of the litigation costs of the other (to the extent not previously reimbursed). Any remaining recoveries shall be allocated as follows:
|
(a)
|
for any suit that is initiated by Licensee and in which Penn was not a party in the litigation, Penn shall receive [***] of the recovery and the Licensee shall receive the remainder; and
|
(b)
|
for any suit that is initiated by the Licensee or Penn and that the other Party joins voluntarily (but only to the extent such voluntary joining is allowed under this Agreement or expressly by the other Party in a separate agreement) or involuntarily, the non-initiating party’s percentage of the total litigation costs incurred by Penn and Licensee, but in no event shall the non-initiating Party receive less than [***] of such recovery, while the initiating party shall receive the remainder, and in no case shall Penn receive less than [***] of such recovery.
|
(c)
|
for any suit that is initiated by Licensee or Penn and the other Party voluntarily but only to the extent such voluntary joining is allowed under this Agreement or expressly by the other Party in a separate agreement) or involuntarily, the initiating party shall receive [***] and the non-initiating shall receive the remainder; and
|
(d)
|
for any suit that is initiated by Licensee and in which Penn was not a party in the litigation, Penn shall receive [***] and Licensee shall receive the remainder.
|
6.3.6
|
Each Party will reasonably cooperate and assist with the other in litigation proceedings instituted hereunder but at the expense of the Party who initiated the suit (unless such suit is being jointly prosecuted by the Parties). For clarity, such requirement does not require a Party to join a suit unless otherwise specifically required under this Agreement. If Penn is subjected to third party discovery related to the Penn Patent Rights or Licensed Products licensed to Licensee hereunder, Licensee will pay Penn’s documented out-of-pocket expenses with respect to same.
|
6.3.7
|
Penn shall keep Licensee reasonably informed of the initiation and status of any action to enforce any Penn Patent Rights A, Penn Patent Rights B, Penn Patent Rights C or Manufacturing Patent Rights pertaining to the Indications or a Licensed Product.
|
6.4
|
Defense
. Each Party shall have the right to defend any adversarial legal proceeding brought against it, and the Parties shall reasonably cooperate with one another regarding such defense, provided that such right of defense does not include any right to bring infringement actions (including counterclaims) with respect to Penn Patent Rights except as expressly set forth herein or as otherwise agreed by the Parties.
|
6.5
|
Patent Marking
. Licensee shall place in a conspicuous location on any Licensed Product (or its packaging where appropriate and practicable) made or sold under this Agreement a patent notice in accordance with the Laws concerning the marking of patented articles where such Licensed Product is made or sold, as applicable.
|
6.6
|
Ownership of Inventions
. Ownership of any inventions or other intellectual property generated in the conduct of the Research Program or otherwise under this Agreement will be determined in accordance with United States patent law or other applicable intellectual property law. For clarity, (a) inventions conceived and reduced to practice solely by Penn inventors will be solely owned by Penn, (b) inventions conceived and reduced to practice solely by Licensee inventors will be solely owned by Licensee, and (c) inventions jointly conceived and reduced to practice by both Penn and Licensee inventors will be jointly owned by Penn and Licensee.
|
7.1
|
Confidential Information
. Licensee shall not disclose Confidential Information to Penn unless it is reasonably necessary to the performance of the Research Program or otherwise required to perform Licensee’s obligations under this Agreement. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, during the Term and for ten (10) years thereafter, the receiving Party (the “
Receiving Party
”) and its Affiliates will keep confidential and will not publish or otherwise disclose or use for any purpose any Confidential Information, which is disclosed to it by the other Party (the “
Disclosing Party
”) or its Affiliates or otherwise made available to a Receiving Party in the course of performing its obligations or exercising its rights under this Agreement. A Receiving Party shall also have the right to disclose the disclosing Party’s Confidential Information to those of the Receiving Party’s and its Affiliates’ employees, agents and/or consultants who have a need to know such Confidential Information to perform its obligations or exercise its rights under this Agreement; and who have entered into a written agreement with the Receiving Party (or its relevant Affiliate) to be bound by the obligations of confidentiality and non-use at least as protective of such Confidential Information as set forth in this Article 7. In the case of Licensee as the Receiving Party, Licensee and its Affiliates shall have the right to use and disclose Confidential Information of Penn: for the purpose of developing, seeking and obtaining Regulatory Approval for, making, having made, using, selling, offering for sale and/or otherwise commercializing Licensed Products under the License; and to actual and potential Third Party service providers, sublicensees, other sources of financing and/or acquirers or others on a need-to-know basis under appropriate conditions of confidentiality.
|
7.2
|
Disclosures Required by Law
. In the event a Party is required to make a disclosure under Law or regulation, the order of a court of competent jurisdiction, or the rules of the U.S. Securities and Exchange Commission or other Governmental Body within or outside the United States (including by reason of any securities offering by Licensee), or any stock exchange or listing entity, a Receiving Party shall provide prompt written notice to the Disclosing Party and take all reasonable steps to limit the extent of the disclosure and obtain confidential treatment for any remaining required disclosure.
|
7.3
|
Penn Intellectual Property
. In order to preserve the patentability of Penn intellectual property and to preserve Penn’s publication rights, Licensee shall maintain Penn Patent Rights, Research Results and Confidential Information provided by Penn pursuant to the Research Program (whether oral or written) as confidential and shall not disclose such Confidential Information to any Third Party except as permitted under this Article 7 until the publication of such information by Penn or until Penn provides Licensee with written verification that all desirable patentable inventions have been protected, whichever occurs sooner.
|
7.4
|
Licensee Intellectual Property
. In order to preserve the patentability of Licensee’s intellectual property and otherwise to preserve Licensee’s rights therein and thereto, Penn shall maintain Amicus Technology and Confidential Information provided by Licensee pursuant to the Research Program or otherwise under this Agreement as confidential and shall not disclose such information to any Third Party except as expressly permitted under this Agreement. For the avoidance of doubt, for purposes of this Agreement, all records maintained by Licensee described in Section 4.10 and all Amicus Technology, Progress Reports and Financial Reports provided by Licensee to Penn under this Agreement, as well as the sequence of any Designated Product, shall be Confidential Information of Licensee.
|
7.5
|
Publications
. Penn shall have the first right to publish, present or otherwise disclose Research Results or other information and material resulting from the Research Program for any purpose; provided, however, that consistent with the Wilson Lab’s standard operating procedures for collaborations with commercial third parties, Penn shall provide Licensee the opportunity to review and comment on any proposed manuscripts or any other proposed public disclosure describing work developed under the Research Program that has not previously been disclosed, [***] prior to its submission for publication or first public disclosure for manuscripts and [***] prior to its submission or first public disclosure for abstracts and speaking engagements to (a) determine whether such contains any Licensee Confidential Information and (b) enable Licensee to identify any Penn intellectual property or joint intellectual property that it wishes Penn to file patent applications on or to seek other intellectual property protection for. If within the [***] or [***] review period (i) Licensee notifies Penn in writing that the Licensee requires deletion from the publication or presentation of Licensee Confidential Information, the Parties will cooperate to modify the disclosure to ensure Licensee Confidential Information is not disclosed or (ii) if Licensee requests in writing that publication or presentation be delayed to allow for patent filings or other intellectual property protection on certain items in the proposed publication or presentation, Penn shall delay the publication or presentation for up to [***] to allow for the filing of applicable patent applications.
|
8.1
|
Mutual Representations and Warranties
. Each Party represents and warrants to the other Party that, as of the Effective Date:
|
8.1.1
|
such Party is duly organized and validly existing under the Laws of the jurisdiction of its incorporation or organization;
|
8.1.2
|
such Party has taken all action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement;
|
8.1.3
|
this Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in accordance with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles; and
|
8.1.4
|
such Party has all right, power and authority to enter into this Agreement, to perform its obligations under this Agreement.
|
8.2
|
Representation of Penn
. Penn hereby represents, as of the Effective Date, to Penn’s knowledge, Penn’s performance of the Research Program and/or grant of rights to Licensee under this Agreement does not directly conflict with any agreement with a Third Party.
|
8.3
|
Disclaimer of Representations and Warranties
.
|
8.3.1
|
Other than the representations and warranties provided in Section 8.1 above,
PENN MAKES NO REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, AND EXPLICITLY DISCLAIMS ANY REPRESENTATION AND WARRANTY, INCLUDING WITH RESPECT TO ANY ACCURACY, COMPLETENESS, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE FOR THE INTELLECTUAL PROPERTY, PATENT RIGHTS, LICENSE AND ANY LICENSED PRODUCT
.
|
8.3.2
|
Furthermore, nothing in this Agreement will be construed as:
|
(a)
|
A representation or warranty by Penn as to the validity or scope of any Penn Patent Right;
|
(b)
|
A representation or warranty that anything made, used, sold or otherwise disposed of under the License is or will be free from infringement of patents, copyrights, trademarks or any other forms of intellectual property rights or tangible property rights of Third Parties;
|
(c)
|
Obligating Penn to bring or prosecute actions or suits against Third Parties for patent, copyright or trademark infringement; and
|
(d)
|
Conferring by implication, estoppel or otherwise any license or rights under any Patent Rights of Penn other than Penn Patent Rights as defined herein, regardless of whether such Patent Rights are dominant or subordinate to Penn Patent Rights.
|
8.4
|
Covenants of Licensee
.
|
8.4.1
|
Licensee and its Affiliates will not, directly or indirectly (including where such is done by a Third Party on behalf of Licensee or its Affiliates) make any Challenge; provided, however, that if any Penn Patent Right is asserted against Licensee or its Affiliate, then such Licensee or its Affiliates is entitled to all and any defenses available to it including challenging the validity or enforceability of such Patent Right.
|
8.4.2
|
Licensee will comply in all material respects with all Laws that apply to its activities or obligations under this Agreement. For example, Licensee will comply with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of the United States Government and/or written assurances by Licensee that Licensee will not export data or commodities to certain foreign countries without prior approval of the agency.
|
8.4.3
|
Licensee will not grant a security interest in the License or this Agreement.
|
9.1
|
Indemnification by Licensee
.
|
9.1.1
|
Licensee shall defend, indemnify and hold Penn and its respective trustees, officers, faculty, students, employees, contractors and agents (the “
Penn Indemnitees
”) harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys’ fees), including, without limitation, bodily injury, risk of bodily injury, death and property damage (collectively, “
Liabilities
”) to the extent arising out of Third Party claims or suits [***]:
|
(a)
|
the gross negligence, recklessness or wrongful intentional acts or omissions of Licensee, its Affiliates or Sublicensees and its or their respective directors, officers, employees and agents, in the performance of the Licensee’s obligations or exercise of Licensee’s rights under this Agreement;
|
(b)
|
any material breach of this Agreement by Licensee;
|
(c)
|
the development, manufacturing or commercialization of Licensed Products (including commercial manufacturing, packaging and labeling of Licensed Products, and all product liability losses of a Licensed Product by or on behalf of Licensee or its Affiliates or Sublicensees; and
|
(d)
|
any enforcement action or suit brought by Licensee against a Third Party for infringement of Penn Patent Rights or Joint Patent Rights.
|
9.1.2
|
As a condition to a Penn Indemnitee’s right to receive indemnification under this Section 9.1, Penn shall: (a) promptly notify Licensee as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto; (b) fully cooperate, and cause the individual Penn Indemnitees to fully cooperate, with Licensee in the defense, settlement or compromise of such claim or suit; and (c) permit the Licensee to control the defense, settlement or compromise of such claim or suit, including the right to select defense counsel. In no event, however, may Licensee compromise or settle any claim or suit in a manner which (i) admits fault or negligence on the part of Penn or any other Penn Indemnitee; (ii) commits Penn or any other Penn Indemnitee to take, or forbear to take, any action, without the prior written consent of Penn, or (iii) grant any rights under the Penn Patent Rights except for Sublicenses permitted under Article 3. Penn shall fully cooperate, and cause the individual Penn Indemnitees to fully cooperate, with Licensee and its counsel in the course of the defense or settlement of any such suit, claim or demand, such cooperation to include without limitation providing or making available documents, information and witnesses.
|
9.1.3
|
Notwithstanding Section 9.1.2 above, a Penn Indemnitee shall be entitled to participate in, but not control, the defense of a Third Party claim or suit subject to indemnification under Section 9.1.1 above and to engage counsel of its own choice for such purpose; provided that such engagement shall be at such Penn Indemnitee’s own expense unless a bona fide conflict exists between Licensee and Penn or any other Penn Indemnitee with respect to a claim or suit subject to indemnification hereunder, such that representation by Licensee and Penn or such other Penn Indemnitee by the same legal counsel due to a misalignment of interests or would be prohibited under applicable law, ethical rules or equitable principles, in which case, Licensee will either pay any reasonable, documented out-of-pocket attorney’s fees and litigation expenses of such Penn Indemnitee directly or reimburse Penn within [***] of Licensee’s receipt of invoices for such fees and expenses.
|
9.1.4
|
In no event shall Licensee be liable under this Section 9.1 for any settlement, compromise or other disposition of a Third Party claim or suit for which a Penn Indemnitee seeks indemnification hereunder and that is reached without the prior written consent of Licensee, such consent not to be unreasonably withheld, conditioned or delayed.
|
9.2
|
Insurance
.
|
9.2.1
|
Licensee, at its sole cost and expense, must insure its activities in connection with the exercise of its rights under this Agreement and keep in force and maintain Commercial Form General Liability Insurance (contractual liability included) with at least the following limits:
|
(a)
|
Each occurrence $[***];
|
(b)
|
General aggregate $[***]
|
(c)
|
Clinical trials liability insurance $[***]
|
(d)
|
Products liability insurance $[***]
|
9.2.2
|
If the above insurance is written on a claims-made form, it shall continue for three (3) years following termination or expiration of this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date of this Agreement.
|
9.2.3
|
Licensee expressly understands, however, that the coverages and limits in Section 9.2.1 do not in any way limit Licensee’s liability or indemnification obligations. Licensee’s insurance will:
|
(a)
|
Be issued by an insurance carrier with an A.M. Best rating of “A” or better;
|
(b)
|
Provide for thirty (30) day advance written notice to Penn of any modification;
|
(c)
|
State that Penn is endorsed as an additional insured with respect to the coverages in Section 9.2.1; and
|
(d)
|
Include a provision that the coverages will be primary and will not participate with nor will be excess over any valid and collective insurance or program of self insurance carried or maintained by Penn.
|
9.2.4
|
Licensee must furnish to Penn with (a) valid certificate of insurance evidencing compliance with all requirements of this Agreement and (b) additional insured endorsements for Licensee’s applicable policies naming “The Trustees of the University of Pennsylvania” as an additional insured. Licensee must furnish both documents within thirty (30) days of the Effective Date, once per year thereafter and at any time there is a modification in such insurance.
|
9.3
|
LIMITATION OF LIABILITY
. [***], IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS OR OPPORTUNITY, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF; PROVIDED THAT NOTHING IN THIS SECTION 9.3 SHALL BE DEEMED TO LIMIT LICENSEE’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 9.1.
|
10.1
|
Term
. The term of this Agreement (the “
Term
”) shall commence on the Effective Date and, unless terminated sooner as provided below, shall continue in full force and effect on a country-by-country and Licensed Product-by-Licensed Product basis until [***]. Following expiration of the [***] (but not earlier termination) in a particular country, the license to Licensed Know-How in such country for Licensed Products for the applicable Indication in the Field of Use as set forth in Section 3.1 will become perpetual and fully paid-up.
|
10.2
|
Termination of the Agreement for Convenience
. Subject to Section 10.4, Licensee may, at its convenience, terminate this entire Agreement or on an Indication-by-Indication basis, by providing at least [***] prior written notice to Penn of such intention to terminate.
|
10.3
|
Termination For Cause
.
|
10.3.1
|
In the event Licensee fails to achieve any Diligence Event by the applicable Achievement Date (or as extended according to the terms of Section 5.7 hereto) other than due to a an Extension Event, Penn has the right and option to terminate this Agreement upon written notice to Licensee on an Indication-by-Indication basis for the Indication for which the Diligence Event has not been achieved, if Licensee has not cured such failure within [***] of written notice from Penn.
|
10.3.2
|
In addition to all other remedies available to it, Penn may terminate this Agreement upon [***] written notice if Licensee materially fails to comply with any Laws that apply to its activities or obligations under this Agreement and that can be remedied and Licensee fails to remedy such lack of compliance within such [***] period, (b) upon [***] written notice, if Licensee grants a security interest in this Agreement or any of the rights granted herein and does not revoke such grant prior to the expiration of such [***] period, or (d) upon written notice, if Licensee breaches Section 8.3.1 and does not withdraw or discontinue the applicable Challenge within [***] of such notice.
|
10.3.3
|
If either Party materially breaches any of its material obligations under this Agreement, the non-breaching Party may give to the breaching Party a written notice specifying the nature of the default, requiring it to cure such breach, and stating its intention to terminate this Agreement. If such breach is not cured within [***] of such notice (for non-payment), and [***] of such notice for all other material breaches, such termination shall become effective upon a notice of termination by the terminating Party thereafter; provide that if there is a good faith dispute as to the existence of a material breach, such [***] period may be extended by mutual agreement of the Parties to allow the Parties additional time to continue good faith discussions to resolve the dispute. To the extent Licensee’s material breach relates solely to an Indication, Penn’s right to terminate the Licensee’s rights under the Agreement will be limited to such Indication.
|
10.3.4
|
Either Party may terminate this Agreement, upon written notice if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of such Party or of its assets, or if such Party proposes a written agreement of composition or extension of its debts, or if such Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within [***] after the filing thereof, or if such Party proposes or is a party to any dissolution or liquidation, or if such Party makes an assignment for the benefit of its creditors of all or substantially all its assets (in each case, “
Bankruptcy Action
”).
|
10.4
|
Effects of Termination
.
|
10.4.1
|
Notwithstanding the termination of this Agreement, the following provisions shall survive: Sections [***] and Articles [***].
|
10.4.2
|
Termination of this Agreement shall not relieve the Parties of any obligation or liability that, at the time of termination, has already accrued hereunder, or which is attributable to a period prior to the effective date of such termination. Termination of this Agreement shall not preclude either Party from pursuing all rights and remedies it may have hereunder or at Law or in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation.
|
10.4.3
|
If this Agreement is terminated for any reason, all outstanding Sublicenses (including all Sublicense Documents for each Sublicense) not in default shall survive, provided that each such Sublicensee agrees in writing to be bound by the applicable terms of this Agreement with respect to the activities of such Sublicensee under such Sublicensee. The duties and obligations of Penn under any surviving Sublicenses will not be greater than the duties of Penn under this Agreement, and the rights of Penn under any surviving Sublicenses will not be less than the rights of Penn under this Agreement, including all financial consideration and other rights of Penn.
|
10.4.4
|
Within [***] of termination of this Agreement or any Indication (other than termination by Licensee pursuant to Section 10.3.3 or 10.3.4), Licensee shall pay Penn
any unpaid portion of the Research Support Amount, and all costs for commitments pertaining to the performance of the Research Plan (to the extent such costs are non-cancellable commitments incurred prior to the receipt, or issuance, by Penn of the notice of termination, and the cost of each employee, student and faculty member allocated to activities under the Research Plan during the Research Term, in each case, to the extent such costs are not included in the Research Support Amount).
|
10.4.5
|
Upon termination of this Agreement and subject to Section 10.3.3, Licensee, its Affiliates and Sublicensees whose rights do not survive termination of this Agreement will promptly cease selling the Licensed Product(s) subject to such termination. Each Party will return (or destroy, as directed by the other Party) all data, files, records and other materials containing or comprising the other Party’s Confidential Information with respect to this Agreement, except to the extent such Confidential Information is necessary or useful to conduct activities in connection with surviving portions of or rights pursuant to this Agreement. Notwithstanding the foregoing, the Parties will be permitted to retain one copy of such data, files, records, and other materials for archival and legal compliance purposes.
|
11.1
|
Relationship of the Parties
. Nothing in this Agreement is intended or shall be deemed, for financial, tax, legal or other purposes, to constitute a partnership, agency, joint venture, fiduciary or employer-employee relationship between the Parties. The Parties are independent contractors and at no time will either Party make commitments or incur any charges or expenses for or on behalf of the other Party.
|
11.2
|
Expenses
. Except as otherwise provided in this Agreement, each Party shall pay its own expenses and costs incidental to the preparation of this Agreement and to the consummation of the transactions contemplated hereby
|
11.3
|
Use of Names
. Licensee, its Affiliates and Sublicensees may not use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Penn or any Penn school, organization, employee, student or representative in any press release, advertising, promotional or sales literature, without the prior written consent of Penn. Notwithstanding the foregoing, Licensee may use the name of Penn in a non-misleading and factual manner solely in (a) executive summaries, business plans, offering memoranda and other similar documents used by Licensee for the purpose of raising financing, including for the operations of Licensee as related to a Licensed Product, or entering into commercial contracts with Third Parties, but in such case only to the extent necessary to inform a reader that the Penn Patent Rights has been licensed by Licensee from Penn, and (b) any securities reports required to be filed with the Securities and Exchange Commission or any other disclosures required under applicable Laws (including securities regulations).
|
11.4
|
No Discrimination
. Neither Penn nor Licensee will discriminate against any employee or applicant for employment because of race, color, sex, sexual orientation, age, religion, national or ethnic origin, handicap, or veteran status.
|
11.5
|
Successors and Assignment
.
|
11.5.1
|
The terms and provisions hereof shall inure to the benefit of, and be binding upon, the Parties and their respective successors and permitted assigns.
|
11.5.2
|
Neither Party may assign or transfer this Agreement or any of its rights or obligations created hereunder, by operation of law or otherwise, without the prior written consent of the other Party. Notwithstanding the foregoing, without Penn’s consent, Licensee shall have the right to assign any of its rights or obligations under this Agreement, or to transfer this Agreement, to: (a) any of its Affiliates, [***]; or (b) a Third Party in connection with a merger, acquisition of all or substantially all of the business or assets of Licensee(whether by sale of stock or assets), consolidation, change of control or other similar transaction; provided that such third party is bound by the terms of this Agreement, by operation of law or otherwise.
|
11.5.3
|
Any assignment not in accordance with this Section 11.5 shall be null and void.
|
11.6
|
Further Actions
. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
|
11.7
|
Entire Agreement of the Parties; Amendments
. This Agreement, the Exhibits and Appendices or Schedules hereto constitute and contain the entire understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject matter. No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party.
|
11.8
|
Governing Law
. This Agreement shall be governed by and interpreted in accordance with the laws of the Commonwealth of Pennsylvania, excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of the Commonwealth of Pennsylvania.
|
11.9
|
Dispute Resolution
. If a dispute arises between the Parties concerning this Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute. Prior to initiation of outside dispute resolution or termination of the Agreement for a material breach, each Party shall escalate such issue to the Chief Executive Officer of Licensee and Dean of Medicine for Penn and such parties will engage in good faith discussions with regard to the applicable dispute within fifteen (15) days. If the Parties are unable to resolve such dispute amicably through good faith discussion and such escalation within thirty (30) days, then either Party may submit to the exclusive jurisdiction of, and venue in, the state and Federal courts located in the Eastern District of Pennsylvania.
|
11.10
|
Notices and Deliveries
. Any notice, request, approval or consent required or permitted to be given under this Agreement shall be in writing and directed to a Party at its address or facsimile number shown below or such other address or facsimile number as such Party shall have last given by notice to the other Party. A notice will be deemed received: if delivered personally, on the date of delivery; if mailed, five (5) days after deposit in the United States mail; if sent via courier, one (1) business day after deposit with the courier service; or if sent via facsimile, upon receipt of confirmation of transmission provided that a confirming copy of such notice is sent by certified mail, postage prepaid, return receipt requested.
|
For Penn
|
with a copy to
:
|
|
|
Penn Center for Innovation
University of Pennsylvania
3160 Chestnut Street, Suite 200
Philadelphia, PA 19104-6283
Attention: Managing Director
|
University of Pennsylvania
Office of General Counsel
133 South 36th Street, Suite 300
Philadelphia, PA 19104-3246
Attention: General Counsel
|
|
|
For Licensee:
|
with a copy to
:
|
|
|
Amicus Therapeutics, Inc.
|
Wilson Sonsini Goodrich & Rosati
|
1 Cedar Brook Drive
Cranbury, NJ 08512
|
12235 El Camino Real
San Diego CA 92130
|
Attention: General Counsel and Corporate Secretary
|
Attention: Miranda Biven
|
|
|
|
|
11.11
|
Waiver
. A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party.
|
11.12
|
Severability
. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under law, but if any provision of this Agreement is held to be prohibited by or invalid under law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.
|
11.13
|
Interpretation
. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” All references herein to Articles, Sections, Schedules and Exhibits shall be deemed references to Articles and Sections of, Schedules and Exhibits to, this Agreement unless the context shall otherwise require. Except as otherwise expressly provided herein, all terms of an accounting or financial nature shall be construed in accordance with GAAP, as in effect from time to time. Unless the context otherwise requires, countries shall include territories. References to any specific Law or article, section or other division thereof, shall be deemed to include the then-current amendments or any replacement Law thereto.
|
11.14
|
Counterparts
. This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Agreement, including the signature pages, will be deemed an original.
|
THE TRUSTEES OF THE UNIVERSITY OF
PENNSYLVANIA
|
|
AMICUS THERAPEUTICS, INC.
|
|
|
|
By:
/s/ John S. Swartley, PhD
|
|
By:
/s/ John F. Crowley
|
Name: John S. Swartley, PhD
|
|
Name: John F. Crowley
|
Title: Associate Vice Provost for Research and Managing Director, Penn Center for Innovation
|
|
Title: Chairman and CEO
|
AMICUS THERAPEUTICS, INC.
By:
___________________________________
Name: David Clark
Title: Chief People Officer, Human Resources
EMPLOYEE:
WILLIAM D. BAIRD III
|
1.
|
Callidus Biopharma, Inc. (Delaware)
|
2.
|
Celenex, Inc. (Delaware)
|
3.
|
Scioderm, Inc. (Delaware)
|
4.
|
Scioderm Limited (Ireland)
|
5.
|
MiaMed, Inc. (Delaware)
|
6.
|
Amicus Therapeutics International Holding Limited (UK)
|
7.
|
Amicus Therapeutics UK Limited (UK)
|
8.
|
Amicus Therapeutics SAS (France)
|
9.
|
Amicus Therapeutics B.V. (Netherlands)
|
10.
|
Amicus Therapeutics GmbH (Germany)
|
11.
|
Amicus Therapeutics S.L.U. (Spain)
|
12.
|
Amicus Therapeutics S.r.l. (Italy)
|
13.
|
Amicus Therapeutics K.K. (Japan)
|
14.
|
Amicus Therapeutics Canada Inc. (Canada)
|
15.
|
Amicus Therapeutics PTY LTD (Australia)
|
16.
|
Amicus Therapeutics US, Inc. (Delaware)
|
17.
|
Amicus Biologics, Inc. (Florida)
|
18.
|
Amicus Therapeutics ApS (Denmark)
|
19.
|
Amicus Therapeutics Europe Limited (Ireland)
|
1.
|
Registration Statement (Form S-3ASR No. 333-212414) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers
|
2.
|
Registration Statement (Form S-3ASR No. 333-211005) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers
|
3.
|
Registration Statement (Form S-3ASR No. 333-207210) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers
|
4.
|
Registration Statement (Form S-8 No. 333-197202) pertaining to the Amicus Therapeutics, Inc. Cash Deferral Plan
|
5.
|
Registration Statement (Form S-8 No. 333-195194) pertaining to the Amicus Therapeutics, Inc. Restricted Stock Unit Deferral Plan
|
6.
|
Registration Statement (Form S-8 No. 333-174900) pertaining to the: 1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. Amended and Restated 2007 Director Option Plan
|
7.
|
Registration Statement (Form S-8 No. 333-157219) pertaining to the: 1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. 2007 Director Option Plan
|
8.
|
Registration Statement (Form S-8 No. 333-145305) pertaining to the: 1) Amicus Therapeutics, Inc. 2002 Equity Incentive Plan, as Amended, 2) Amicus Therapeutics, Inc. 2007 Equity Incentive Plan, 3) Amicus Therapeutics, Inc. 2007 Director Option Plan, 4) Amicus Therapeutics, Inc. 2007 Employee Stock Purchase Plan
|
9.
|
Registration Statement (Form S-3 No. 333-192747), pertaining to the acquisition of Callidus Biopharma, Inc.
|
10.
|
Registration Statement (Form S-3 No. 333-192876), pertaining to the issuance of warrants
|
/s/ John F. Crowley
|
John F. Crowley
|
Chairman and Chief Executive Officer
|
/s/ Daphne Quimi
|
Daphne Quimi
|
Chief Financial Officer
|
/s/ John F. Crowley
|
John F. Crowley
Chairman and Chief Executive Officer
|
February 28, 2019
|
/s/ Daphne Quimi
|
Daphne Quimi
Chief Financial Officer
|
February 28, 2019
|